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CHAPTER 1
INTRODUCTION

Please note that part of this chapter was taken from a book chapter titled
“Intracellular Delivery Considerations for RNAi Therapeutics” to be published in
RNA Interference from Biology to Therapeutics, K. A. Howard, Ed., Springer,
New York, 2012 (in press). The authors of the book chapter include Yu Zhu, Prof.
David Oupicky, and me. All the authors agreed with including their work in this
dissertation.

1.1 Gene Therapy
Gene therapy is the introduction of genetic materials into an individual’s
cells and tissues to treat or prevent a disease. Gene therapy was first regarded
as best-suited for treating inherited disorders caused by single gene defects such
as cystic fibrosis. However, during the past three decades, the definition and
scope of gene therapy evolved to include diseases caused by multiple gene
mutations such as cancer, immunodeficiencies, or Parkinson’s disease. Common
strategies for gene therapy include (i) replacing a gene that causes the disease
with a healthy, functional copy; (ii) silencing a mutated gene or knocking-down an
overexpressed gene; (iii) introducing a new therapeutic gene for treating the
disease (Stoff-Khalili, Dall et al. 2006).
Viral vectors and synthetic vectors are two major classes of delivery
systems used for gene therapy. Viral vectors utilize the virus infection pathway to
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introduce their genetic material into the host cells as part of their replication
cycle. The viral genetic material is usually engineered by deleting the coding
regions of the viral genome, replacing them with therapeutic genes, and leaving
sequences required for virus packaging and integration. Viral vectors exhibit
advantages of high transfection efficiency and capability to transduce nondividing cells, however, the arising immunogenicity and tumorigenicity concerns
make non-viral gene delivery vectors preferred alternative. Despite all the efforts
devoted to the design and development of non-viral vectors their transfection
efficiency remains low and not comparable with viral vectors. As a result, only a
small number of non-viral products are mature enough for clinical trials,
compared with the large number of clinical trials in the past 20 years that utilize
viral vectors.

3

Figure 1. Number of gene therapy clinical trials approved worldwide from 1989 to
2012. (Source: The Journal of Gene Medicine)
Ever since the approval of the first human gene therapy clinical trial for
treating severe combined immunodeficiency (SCID) in 1990 (Blaese, Culver et al.
1995), the total number of clinical trials for gene therapy worldwide has increased
rapidly (Figure 1). Impressive progress has been made during the past years,
including the first gene therapy drug entering the market in China. However,
during this period, there were also times when incidents during clinical trials set
gene therapy field back because of the reported serious adverse effects.
The overview of gene therapy clinical trials since 1989 compiled by the
Journal of Gene Medicine reveals some interesting facts about the gene therapy
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field worldwide (Figure 2). Concerning the indications addressed by the clinical
trials throughout the years, the majority of the trials are aimed at treating cancer
(64.4%), followed by monogenic diseases (8.7%) and cardiovascular diseases
(8.4%). Among the hundreds of different genes that have been introduced into
humans during gene therapy clinical trials, around 60% of the genes are related
to cancer treatment. Although non-viral vectors have become more popular in the
area of basic research, viral vectors continue to dominate the clinical trials so far.
The interest in using naked DNA as the simplest non-viral vector has increased
to 18.3%, followed by the second most popular non-viral vectors, cationic lipids,
at 5.9%. The vast majority of gene therapy clinical trials are still in phase I or II (a
total of 95.3%) and only 0.1% has ever moved to phase IV. The number of
countries that have participated in performing gene therapy clinical trials has
increased to 31 from 28 in 2007. The USA still accounts for most of the trials
(63.7%) with a slight but continuous drop compared with 67% in 2004 and 64.2%
in 2007.
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Figure 2. Gene Therapy clinical trials categorized based on disease indication,
vector used, clinical trial phase, and geographical distribution by country to 2012.
(Source: The Journal of Gene therapy)
Concerns from the researchers as well as the public regarding safety and
potential side effects of gene therapy procedures using genetically engineered
viruses have never been stopped (Edelstein, Abedi et al. 2007). On September
17, 1999, the first major adverse incident of gene therapy occurred (Raper,
Chirmule et al. 2003), which was widely viewed as a major setback of the gene
therapy field. 18-year-old Jesse Gelsinger, who was a patient with ornithine
transcarbamylase (OTC) deficiency and participated in a clinical trial of
adenovirus-based vector, died due to devastating and unexpected immune
response to the virus. In January 2000, the US Food and Drug Administration
(FDA) put a hold on the trial and several other related trials were also stopped.
The final judgment in the Gelsinger case in February 2005 led to $517,000
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settlement. FDA also adjusted their research restrictions and guidelines for gene
therapy clinical trials, including prolonged observation time for delayed adverse
effects. Concerns regarding safety of using retrovirus have been raised after a
number of major adverse events in several clinical trials for treating X-linked
severe combined immune deficiency (X-SCID) and chronic granulomatous
disease (CGD) (Gansbacher 2002; Check 2003; Gansbacher 2003; Kohn and
Gansbacher 2003; 2006) and the negative attitude towards virus-based gene
therapy from the press cover and the public have dampened the enthusiasm of
the field.
Despite the setbacks, numerous promising pre-clinical studies and a large
number of successful cases of human gene therapy have shown the great
potential of the field, especially for cancer gene therapy and for treating
Parkinson’s disease (Morgan, Dudley et al. 2006; Edelstein, Abedi et al. 2007).
Although there are no current gene therapy products in the United States, China
has pushed the approval and marketing of the first gene therapy drug worldwide.
GendicineTM is an adenoviral vector containing recombinant human p53 tumor
suppressor gene used as a local injection in the treatment of the head and neck
squamous cell carcinoma (HNSCC). The drug was developed by SiBiono
GeneTech Co. of Shenzhen and was approved for clinical use by the Chinese
State Food and Drug Administration (SFDA) in the fall 2003 and became
available on the market in the spring 2004. However, the approval of the drug
was achieved without the standard phase III trial data and the quality, safety as
well as the efficacy of the treatment have been questioned by several research

7
groups (Edelstein, Abedi et al. 2007). Despite the issues mentioned above,
increasing number cancer patients from around the world has traveled to China
and been treated with Gendicine. One can hope that the increasing experience
and collected data will be made public to diffuse existing concerns with the
treatment.

1.2 Nucleic Acids for Gene Therapy
One of the major advantages of using non-viral gene delivery vectors is
the versatility of using different type of therapeutic nucleic acids and the ease of
formulation development. This section will focus on different types of nucleic
acids that could be used in gene therapy and their current applications.

1.2.1 Plasmid DNA (pDNA)
pDNA is a simple gene therapy vehicle that can be easily designed and
produced in vitro from bacteria or bacteria-derived products. This unique circular
double-stranded form of engineered nucleic acids could be used to code for a
single protein of interest, and not be associated with any other proteins. The
gene of interest could be inserted into the plasmid backbone with replication
function only in bacteria. pDNA is usually large in size ranging from 2 to 15 kbps.
It typically contains three basic elements: (i) an origin of replication which is
active in bacteria; (ii) a prokaryotic expression cassette, including prokaryotic
promoter and terminator of transcription that codes for an antibiotic-resistance
protein; (iii) an eukaryotic expression cassette including eukaryotic promoter,
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start codon in Kozak surrounding, coding sequence, stop codon and terminator
of transcription for the protein product of interest (Weide, Garbe et al. 2008).
pDNA requires delivery to the cell nucleus to reach the transcription machinery
and production of mRNA and subsequent translation into protein product. Many
studies have reported successful delivery of therapeutic pDNA into animal and
human cells. These treatments have improved conditions of the diseases,
including various interleukin genes for immunotherapy and tumor suppressor
genes and pro-apoptotic genes for cancer treatment (Mahato, Lee et al. 2001;
Horton, Lalor et al. 2008; Sun, Zhang et al. 2009; Xu, Zhang et al. 2010; Faham,
Herringson et al. 2011; Kawabata, Baoum et al. 2012; Lee, Nguyen et al. 2012).

1.2.2 Messenger RNA (mRNA)
Interest in the use of mRNA as an alternative to pDNA in gene therapy
has only grown recently, since mRNA has been regarded as too unstable for
practical application (Tavernier, Andries et al. 2011). Structurally, single-stranded
mRNA molecules are a few hundreds up to approximately 10 kb in size obtained
by in vitro transcription of pDNA. They usually contain three basic elements: (i) a
cap structure (methyl-7-guanine followed by three phosphate groups) at the 5′
end; (ii) a coding sequence including the start codon, the coding sequence for
protein of interest and the stop codon; (iii) a poly A-tail of around 30 residues at
the 3′ end (Weide, Garbe et al. 2008). Despite the instability of mRNA
determined by its structure, several research groups have not only proven the
feasibility of using mRNA to achieve high transfection efficiency and prolonged
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protein expression, but they also have been able to demonstrate major
advantages over the use of pDNA (Malone, Felgner et al. 1989; Dwarki, Malone
et al. 1993; Van Tendeloo, Ponsaerts et al. 2001; Rejman, Tavernier et al. 2010).
The first major advantage is that mRNA does not need to be delivered into the
cell nucleus to exert its biological activity. Furthermore, mRNA can only provide a
transient protein expression without the risk of integration into the genome, which
can be safer and advantageous in some applications. Finally, mRNA lacks CpG
motifs (unmethylated cytosine-phosphate-guanine signal present in bacterial and
viral DNA triggering immune responses), and thus its use is expected to be less
immunogenic than the use of pDNA (Krieg, Yi et al. 1995; Tavernier, Andries et
al. 2011). Currently, different delivery techniques and vehicles for mRNA are
been exploited and most attention has been paid to vaccine development (Conry,
LoBuglio et al. 1995; Jarnjak-Jankovic, Pettersen et al. 2005; Bonehill, Van Nuffel
et al. 2009). Other major application areas of mRNA in gene therapy include anticancer immunotherapy (Saeboe-Larssen, Fossberg et al. 2002; Ponsaerts, Van
Tendeloo et al. 2003; Gilboa and Vieweg 2004; Mu, Kyte et al. 2005; Qiu, Lil et
al. 2007), anti-infection immunotherapy (Martinon, Krishnan et al. 1993; Yu,
Babiuk et al. 2007; Roesler, Weiss et al. 2009) and relieving hypoxic stress in the
brain (Martinon, Krishnan et al. 1993; Yu, Babiuk et al. 2007; Roesler, Weiss et
al. 2009).
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1.2.3 Antisense Oligonucleotides (AON)
AON are a type of short single-stranded nucleic acids with about 22-28
bases. AON can be used to target a specific complementary (coding or noncoding) mRNA sequence by Watson-Crick base pairing. The formed DNA/RNA
hybrid is recognized and degraded by RNase H, therefore inhibiting the
expression of a specific mRNA and blocking the genetic transfer from DNA to
protein (Dias and Stein 2002; Chan, Lim et al. 2006). AON do not deliver a new
gene to the target cells, but rather modulate existing gene products (mRNA) or
alter the transcription pathways. A variety of mechanisms mediated by AON
could be used for therapeutic purposes. The most important ones include
reframing of mRNA transcripts by hiding an exon from the splicing machinery and
causing the skipping of exon (Aartsma-Rus and van Ommen 2010); RNase H
knockdown of DNA-RNA hybrids (Marwick 1998; Pan and Clawson 2006);
immune activation through toll-like receptor 9 (Dorn and Kippenberger 2008); and
translation initiation/elongation block (Nasevicius and Ekker 2000; Rayburn and
Zhang 2008). Currently, AON are commonly in use not only in the laboratory to
study specific functions of a specific gene (loss-of-gene function) and valid
therapeutic targets, but also in clinic to be applied as a therapeutic agent to
target various diseases including cancer, AIDS, neuromuscular disorders,
arthritis etc (Ratajczak, Kant et al. 1992; Kim, Tewari et al. 2009; Aartsma-Rus
and van Ommen 2010; Nlend Nlend, Meyer et al. 2010). Fomivirsen has been
the first AON to be approved by the FDA (1998) and introduced to the US market
for the treatment of cytomegalovirus retinitis.
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1.2.4 Small interfering RNA (siRNA) and other RNAi therapeutics
Since RNA interference (RNAi)-based gene silencing by double stranded
RNA was first described in 1998 (Fire, Xu et al. 1998), the field of RNAi-mediated
gene therapy has been quickly developing. Despite the recent setback of RNAi
research and the shutdown of RNAi departments of big pharmaceutical
companies, the rationale and potential of RNAi therapeutics are still strong and
siRNA delivery remains of great interest. There are three major types of RNAi
therapeutics: small interfering RNA (siRNA), microRNA (miRNA) and small
hairpin RNA (shRNA). siRNA is a class of double-stranded RNA (dsRNA)
molecules with 20-25 nucleotides in length. siRNA performs its silencing function
in the cytoplasm by first incorporating into RNA-induced silencing complex
(RISC). siRNA duplex then undergoes unwinding and the sense strand is
excluded from the RISC. RISC-induced mRNA cleavage, which is facilitated by
complementary base pairing with the antisense strand, results in posttranscriptional gene silencing. miRNA is a single strand RNA generated during
endogenous transcription (He and Hannon 2004). It is ~ 22 nucleotides in length,
firstly transcribed in the nucleus as long primary transcripts (pri-miRNA) with local
hairpin structure and then processed into precursor miRNAs (pre-miRNA) by
Drosha enzyme, followed by export to the cytoplasm where it is processed to
form mature miRNA by Dicer (Lee, Jeon et al. 2002). Unlike siRNA, which forms
a perfect duplex with its target mRNA and directs the RISC-mediated mRNA
degradation, the action of miRNA depends on the level of complementarity. It
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may cause mRNA cleavage or it may bind imperfectly with the untranslated
regions of mRNA, leading to translational repression. The endogenous
processing pathway of miRNA improves the silencing efficacy and avoids
activation of the interferon system associated with externally introduced synthetic
siRNA (Boden, Pusch et al. 2004). Depending on the type of miRNA, the desired
intracellular site of delivery varies from cytoplasm to the nucleus. shRNA is a
class of RNAi agents with tight hairpin turn that can be cleaved by Dicer enzyme
to generate siRNA with 21-23 nucleotides. shRNA can be introduced into host
cells via plasmid or virus, and further integrated into the host genome. This gives
advantage of the silencing effect not necessarily being lost or diluted during cell
division. shRNA is used more frequently in the laboratory to achieve permanent
knockdown of a specific mRNA. Unlike siRNA, shRNA is usually delivered as the
corresponding gene inserted into a plasmid DNA, which undergoes transcription
process to form shRNA. Therefore, the sequence encoding for shRNA has to
enter the nucleus and the delivery considerations fall into the DNA delivery
category (Tokatlian and Segura 2010).

1.3 Gene Delivery by Polyplexes
Non-viral vectors for gene delivery have the advantages of simplicity of
use, ease of large-scale production, and possibly a lack of specific immune
response. A variety of non-viral delivery systems can be used for gene therapy,
including complexes of cationic lipids and nucleic acids called lipoplexes
(Felgner, Gadek et al. 1987; Nabel, Nabel et al. 1993; Lee, Marshall et al. 1996;
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Wheeler, Felgner et al. 1996), complexes of cationic polymers and nucleic acids
called polyplexes (Boussif, Lezoualc'h et al. 1995; Roy, Mao et al. 1999; Oupicky,
Konak et al. 2000; Ogris and Wagner 2002), and naked plasmid DNA for use in
electroporation, gene gun or hydrodynamic approaches of delivery (Rols, Delteil
et al. 1998; Liu, Song et al. 1999; Rizzuto, Cappelletti et al. 1999). This section
will focus on the properties and use of polyplexes with emphasis on the
intracellular barriers faced by these delivery systems, and possible strategies of
vector design to overcome these challenges.
For efficient delivery and transfection of various nucleic acids, polyplexes
need to overcome a number of intracellular barriers to successfully deliver and
release the gene cargo in the right subcellular locations. In most cases,
polyplexes are internalized into the cells via endocytosis. Many studies have
shown evidence that multiple endocytic pathways are involved, including clathrinand

caveolae-mediated

pathways,

macropinocytosis

and

phagocytosis

(Goncalves, Mennesson et al. 2004; Rejman, Bragonzi et al. 2005; Vercauteren,
Piest et al. 2011). The relative importance of these different mechanisms of
uptake depends on the used cell line. It remains to be seen which of the
pathways is most beneficial for effective gene delivery although the dominant
view currently favors caveolae pathway as the most favorable. If polyplexes
contain specific targeting ligands that bind to cell surface receptors, they could be
internalized by receptor-mediated endocytosis. Initial uptake of polyplexes
proceeds through a sequence of trafficking vesicles including early endosomes,
late endosomes and lysosomes. If polyplexes successfully escape lysosomal
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degradation, cytosolically active nucleic acids (siRNA, mRNA) require release in
the cytoplasm, while the nuclearly active ones (pDNA, AON, miRNA, shRNA)
require further transport to the nucleus for transcription. Nucleic acids released in
the cytoplasm can be either degraded by cytosolic nucleases or be further
transported to the nucleus as well. Polyplexes that do not disassemble in the
cytoplasm are transported into the nucleus either passively by association with
nuclear material during breakdown of the nuclear envelope during cell division or
actively through nuclear pore complexes. The possibility of active transport of
intact polyplexes through the nuclear pore complex remains controversial despite
many attempts to confirm it.
Cell uptake is the first and one of the key steps required for successful
delivery of polyplexes. Since the cell membrane consists of a hydrophobic
phospholipid

bilayer

embedded

with

various

surface

proteins,

the

physicochemical properties of this biological barrier make direct translocation of
hydrophilic nucleic with negative charge very difficult. Complexation of nucleic
acids with cationic polymers results in a formation of particles (usually nanosized) with a net positive charge, which facilitates interaction with the cell
membrane and triggers polyplex internalization via endocytosis. Evidence shows
that cell uptake of the polyplexes could be improved by modification of the
polycations by attaching various targeting ligands to enhance receptor-mediated
internalization or other lipophilic moieties such as cholesterol to promote fusion
with the cell membrane as well as improve subcellular trafficking (Zidovska,
Evans et al. 2009; Filippov, Konak et al. 2010). Various cell-penetrating peptides
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(CPPs) like TAT trans-activator protein have also been incorporated into the
gene delivery vectors to promote cell uptake and membrane translocation
(Soundara Manickam, Bisht et al. 2005; Ishihara, Goto et al. 2009; Nam, Kim et
al. 2011).
After polyplexes are internalized into the cell, the intracellular trafficking
starts in early endosomes and proceeds through the stage of late endosomes,
which are acidified by a vacuolar-type H+ ATPase membrane proton pump
(Dominska and Dykxhoorn 2010). Without an endosomal escaping mechanism,
free nucleic acids are most likely trapped in the endosomes and are
subsequently routed to the lysosomes where they are exposed to lysosomal
enzymes and degraded (Di Guglielmo, Le Roy et al. 2003). Hence, endosomal
escape is one of the most significant barriers encountered during intracellular
gene delivery. Many successful polyplexes utilize the so-called “proton sponge
effect” to facilitate breaking out of the endosomes and entrance into the
cytoplasm. Polycations with high buffering capacity in the endo/lysosomal pH
range (pH 4.5-6) have the capability of absorbing protons and preventing the
acidification of the endosomes, ultimately resulting in the release of the
polyplexes into the cytoplasm. The proposed mechanism of action relies on
elevated influx of the protons to endosomes mediated by the H+-ATPase. The
increased concentration of the protons and the counter ions in the endosomal
vesicles lead to increasing osmotic pressure, causing endosomal swelling,
membrane rupture and finally the release of the polyplexes into the cytosol
(Sonawane, Szoka et al. 2003; Dominska and Dykxhoorn 2010). Poly(ethylene
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imine) (PEI) was the first and remains the most wildly used polycation based on
the proton sponge hypothesis (Baker, Saltik et al. 1997; Zou, Erbacher et al.
2000; Urban-Klein, Werth et al. 2005; Goyal, Tripathi et al. 2012). The mix of
primary, secondary, and tertiary amines in the PEI chain not only provide multiple
positive charges at physiological conditions to bind with various negatively
charged nucleic acids, but they also act as the proton sponge to facilitate the
endosomal escape (Goyal, Tripathi et al. 2012). Unfortunately, the high cationic
charge density also contributes to high cytotoxicity of PEI, which has impeded its
in vivo applications (Florea, Meaney et al. 2002; Aravindan, Bicknell et al. 2009;
Malek, Merkel et al. 2009). PAMAM dendrimers are another group of polycationic
gene delivery vectors with high buffering capacity. These tree-like polymers have
highly controlled and defined sizes and architecture with surface primary amines
and central tertiary amines. These multiple amino groups provide high buffering
capacity and proton absorbing ability, which can improve the endosomal escape
of the dendrimers (Bielinska, Kukowska-Latallo et al. 1996; Kukowska-Latallo,
Bielinska et al. 1996; Choi, Thomas et al. 2005; Tsutsumi, Hirayama et al. 2007).
Alternative approaches have been applied in vector design to improve
endosomal escape such as using synthetic fusogenic peptides that mimic the
fusion process during virus infection (Oliveira, van Rooy et al. 2007) and
introducing membranolytic peptides from viruses with pore-forming ability (Kwon,
Bergen et al. 2008).
The mechanism of action of pDNA, miRNA and shRNA requires
successful delivery to the cell nucleus. The cytoplasmic environment is
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composed of densely packed soluble proteins and cytoskeleton protein
structures such as actin filaments and microtubules. This dense packing creates
a substantial barrier for trafficking of large delivery vectors because their passive
diffusion is severely limited. The trafficking of the delivery vectors, and
endosomes containing the vectors, mainly relies on microtubules and
kinesin/dynein motor proteins (Leopold, Kreitzer et al. 2000; Kulkarni, Castelino
et al. 2006). Disrupting the microtubule network using nocodazole to
depolymerize tubulin significantly decreases the cytoplasmic transport of the
delivery vectors. In contrast, applying cyclic mechanical stretch to the cells to
reorganize and stabilize the microtubules leads to tubulin acetylation and
enhanced endosomal trafficking leading to improved transfection efficiency
(Geiger, Kaufman et al. 2009).
Early research showed that microinjection of exogenous genes into the
nucleus produced strong gene expression while injection into the cytoplasm
resulted in poor expression (Capecchi 1980; Graessmann, Menne et al. 1989).
These findings clearly demonstrated that the nuclear envelope is a crucial barrier
for delivery of nucleic acids to the nucleus. In rapidly dividing cells, delivery
vectors have the opportunity to access nucleus during the process of mitosis
when the nuclear envelope breaks down and becomes permeable to the material
present in the cytoplasm (Dean, Strong et al. 2005). However, in non-dividing
cells the nuclear envelope is a major barrier for non-viral delivery vectors.
Significant effort has been made in improving nuclear delivery of the polyplexes
and one of the most successful strategies is to incorporate nuclear localization
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signals (NLS) in the vector to target cell nucleus. The conjugated NLS sequence
will guide the polyplexes through the nuclear pore complex into the nucleus
leading to enhanced transfection (Ritter, Plank et al. 2003; Manickam and
Oupicky 2006; Zhang, Mitin et al. 2009).
In summary, to design efficient and safe gene delivery vectors, each and
every intracellular barrier, including cell uptake, endosomal escape, and nuclear
entry, should be taken into consideration. Polycationic vectors allow versatile
design and modification to overcome these intracellular barriers, therefore
representing promising gene delivery vectors not only in in vitro studies but also
future in vivo applications.

1.4 Stimulus-Responsive Polyplexes
Among the different strategies applied in the design of polyplexes, various
stimuli were used to trigger the disassembly of the formed particles and the
release of the carried genetic materials after entering into the cells. Polyplexes
responsive to different stimuli, including pH, hyperthermia, light, and redoxpotential gradient, possess great potential for controlled release of the nucleic
acids (Read, Logan et al. 2005).
Modification of polymeric vector by introducing pH-sensitive linkers is one
of the most common approaches to improve intracellular release and endosomal
escape of the polyplexes. 2,4,6-trimethoxybenzylidene-tris(hydroxymethyl)ethane
(TMB-THME) hydrophobe as a pH-sensitive linker, has been conjugated to PEI
to improve endosomal release of the polyplexes leading to improved transfection
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efficiency in Hela cells (Liu, Zheng et al. 2011). Other research groups have also
tried to modify the classic PEI polymers with pH-sensitive moieties to improve
cell uptake and intracellular release (Wong, Sood et al. 2009). Polyethylene
glycol (PEG) could also be conjugated to PEI via pH-sensitive linkers like aminereactive, endosomal pH cleavable acetal or hydrazone to form bioreversible
surface shielding of DNA polyplexes for controlled release (Knorr, Allmendinger
et al. 2007; Fella, Walker et al. 2008). Functionalization with pH-responsive
moieties have also been applied to other polymeric vectors like poly(L-lysine)
(PLL) such as by incorporation of a charge-reversible poly(aspartamide)
derivative to achieve enhanced endosomal escape and controlled gene delivery
in human umbilical vein endothelial cells (HUVEC) (Sanjoh, Hiki et al. 2010).
Conjugating histidine residues to the PLL polymer backbone to obtain pHsensitive comb shaped polymer has shown improved transfection in 293T cells
compared with unmodified PLL control. The improvement has been ascribed to
enhanced endosomal release of DNA.
Introducing thermo-sensitive moieties to the polyplexes is another popular
strategy to achieve controlled release of the nucleic acids. Pluronic block
copolymers

have

been

shown

to

exhibit

a

thermally

reversible

swelling/deswelling behavior, which triggers endosomal escape of polyplexes.
Nanocapsules prepared from PEI and Pluronic were able to efficiently deliver
siRNA, most likely due to improved endosomal escape (Lee, Choi et al. 2008). It
has also been reported that thermo-responsive polymers that exhibit a lower
critical solution temperature (LCST) behavior could be used to successfully
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transport nucleic acids and release them in response to mild hyperthermia
(Lavigne, Pennadam et al. 2007).
Photosensitive vectors utilize photosensitizers for endosomal disruption.
Upon exposure to light, photosensitizers are stimulated to form reactive oxygen
species leading to the damage of endosomal membranes, causing release of the
RNAi vectors in the cytoplasm. Oliveira et al. has shown that by incorporating
photosensitizers into siRNA delivery vectors which target epidermal growth factor
receptor (EGFR), endosomal escape efficiency of siRNA vectors improved
significantly, resulting in a 10-fold increase in the knockdown efficacy of EGFR
(Read, Bremner et al. 2003; Oliveira, Fretz et al. 2007).

1.5 Redox-Responsive Polyplexes
One of the several stimuli, which has been often utilized for improving the
efficiency of nucleic acid delivery, is the redox potential gradient existing between
extracellular and intracellular environments. The existence of a high redox
potential gradient between oxidizing extracellular space and the reducing
environment of subcellular organelles has been exploited by incorporating
disulfide bonds into the structure of polyplexes to provide them with the capability
to release the therapeutic nucleic acids selectively in the subcellular reducing
space. The original interest in gene delivery systems controlled by redox
potential gradients was guided by the need to transiently enhance stability of the
vectors during the delivery.
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1.5.1 Biological rationale
A redox potential gradient exists between extracellular environment and
various subcellular organelles in normal as well as pathological states. Disulfide
bonds present in the structure of polyplexes are readily reduced in the reducing
intracellular environment, while they are generally preserved in the oxidizing
extracellular space. The intracellular reduction of disulfide bonds in polyplexes is
mediated by thiol/disulfide exchange reactions with small redox molecules like
glutathione (GSH) and thioredoxin; either alone or with the help of redox
enzymes. GSH (L-γ-glutamyl-L-cysteinylglycine) is the most abundant thiol
present in mM concentrations inside the cell but only in µM concentrations in the
blood plasma (Jones, Carlson et al. 1998). GSH has multiple functions in many
critical cellular processes including synthesis of proteins and DNA, amino acid
transport, enzyme activity, metabolism and protection of cells (Meister and
Anderson 1983). GSH also serves as a reductant by functioning to destroy free
radicals, hydrogen peroxide and other peroxides. It also functions as a storage
form of cysteine. The intracellular GSH concentration is an additive function of
both its oxidized (GSSG) and reduced form (GSH). The glutathione redox ratio
([GSH]:[GSSG]) is maintained and determined by the activity of glutathione
reductase, NADPH concentrations, and transaldolase activity. The redox state of
the GSH/GSSG couple is often used as an indicator of the overall redox
environment of the cell. In contrast to other redox systems in the cell, not only the
[GSH]:[GSSG] ratio, but also absolute concentrations of GSH and GSSG are
important for the estimation of the redox state of the cell (Schafer and Buettner
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2001). This is because the Nernst equation for the reduction potential of the
GSH/GSSG couple depends on [GSH]2/[GSSG]. The GSH concentration and
redox ratio ([GSH]:[GSSG]) are different in various subcellular compartments
(Smith, Jones et al. 1996). Because of the different GSH levels in various
subcellular organelles, the local GSH concentration and [GSH]:[GSSG] ratio are
important for predicting the location and rate of the disulfide reduction.
The majority of GSH is usually found in the cytosol (1–11 mM), which is
also the principal site of GSH biosynthesis (Kosower and Kosower 1978; Gilbert
1990; Hwang, Lodish et al. 1995). The most reducing environment in the cell is
usually found within the nucleus, where it is required for DNA synthesis and
repair and to maintain a number of transcription factors in reduced state
(Bellomo, Vairetti et al. 1992; Wu, Bishopric et al. 1996; Arrigo 1999). The
nuclear GSH levels are typically higher than those found in the cytosol and can
reach up to 20 mM (Bellomo, Vairetti et al. 1992; Soboll, Grundel et al. 1995;
Smith, Jones et al. 1996). Another major pool of GSH in the cell is found in
mitochondria (~5 mM) (Wahllander, Soboll et al. 1979; Lash, Putt et al. 2002).
Both mitochondrial and nuclear GSH pools are at least partially independent of
the cytosolic pool. In contrast to the reducing environment found in the nucleus
and mitochondria, the endoplasmic reticulum is more oxidizing than the cytosol
(Braakman, Helenius et al. 1992; Hwang, Sinskey et al. 1992). The ratio
[GSH]:[GSSG] is relatively low, typically ranging from 1:1 to 3:1. In comparison,
the overall ratio in the cell is usually >30:1. One should keep in mind, however,
that the redox state of the cell is not static. It depends on a variety of factors
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including the stage of the cell cycle and biological status of the cell in general
(Schafer and Buettner 2001).
Despite numerous studies, the redox state of endosomes and lysosomes
remains a contested issue. Even though some evidence suggests the possibility
of endosomal and lysosomal reduction of disulfide bonds (Shen, Ryser et al.
1985; Collins, Unanue et al. 1991; Phan, Arunachalam et al. 2000; Fivaz, Vilbois
et al. 2002; Saito, Amidon et al. 2003), recent report provides evidence that both
the endosomal and lysosomal environments are oxidizing (similar to ER) and
disulfide reduction proceeds inefficiently (Austin, Wen et al. 2005). It was
suggested that reductions previously ascribed to endosomes could have
proceeded in Golgi (Feener, Shen et al. 1990). However, one cannot exclude
also the possibility that a small subset of lysosomes could be reducing or that
only

some

disulfides

within

certain

proteins

could

be

susceptible

to

endo/lysosomal cleavage. Because bioreducible polyplexes contain a large
number of disulfides, it is unlikely that the limited reducing potential of
endo/lysosomes plays an important role in their subcellular trafficking. The
subcellular distribution of reducing capability and current understanding of
subcellular trafficking of polyplexes therefore suggests that intracellular reduction
of disulfide bonds in redox-sensitive polyplexes proceeds preferentially in the
cytoplasm and nucleus.

1.5.2 Bioreducible polyplexes
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Introducing reducible disulfide bonds into the backbone of the polycations
allows polyplexes to undergo intracellular thiol-disulfide exchange reactions,
leading to the cleavage of the disulfide bonds and fragmentation of the
polycations. The increased disassembly rate ultimately enhances the intracellular
availability of the nucleic acids that leads to enhanced transfection efficiency
(Read, Bremner et al. 2003; Read, Singh et al. 2005; Soundara Manickam and
Oupicky 2006; Won, Yoon et al. 2011; Beloor, Choi et al. 2012). Another major
advantageous feature of the redox-responsive (bioreducible) polyplexes is that
the disassembly of the polyplexes due to the breakage of disulfide bonds causes
fragmentation of the vector and generates small-molecular-weight molecules,
resulting in significantly decreased cytotoxicity (Jere, Arote et al. 2009; Kim and
Kim 2011).
Numerous bioreducible polymers have been developed, including various
novel types of polycations with unique structure and architecture as well as
simple modifications of the existing non-degradable polycations like PEI. These
polycations typically show improved transfection efficiency and reduced toxicity.
Many of them have demonstrated successful and safe delivery of a variety of
nucleic acids (pDNA, siRNA, AON) both in cell culture and in animal studies.
Bioreducible poly(amido amine)s (PAA) can be synthesized by Michael
addition reaction of a variety of combinations of acrylamide and amine
monomers. It is convenient to develop a panel of PAA using different types of the
monomers and reaction conditions including solvent, temperature and feeding
ratio. Engbersen et al. reported the synthesis of a series of novel bioreducible
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PAA by Michael addition polymerization of a panel of primary amines and
disulfide containing cystamine bisacrylamide (CBA). The polymers were relatively
stable in physiological conditions but could be rapidly degraded in reducing
environment. These PAA also showed improved transfection compared with PEI
in COS-7 cells while showing lower cytotoxicity. The authors have also found that
among the group of bioreducible PAA synthesized for activity screening, the ones
that contained amino alcohol pendant groups exhibited the highest gene delivery
efficiency (Hoon Jeong, Christensen et al. 2007; Lin, Zhong et al. 2007; Lin,
Zhong et al. 2007; Lin, Blaauboer et al. 2008).
Great effort has also been made by many other groups to design the best
performing bioreducible polymeric gene delivery systems for both pDNA and
siRNA including the development of bioreducible poly(β-amino ester) copolymers
(Christensen, Chang et al. 2007; Hoon Jeong, Christensen et al. 2007; Kim,
Jeong et al. 2008; Yockman, Kastenmeier et al. 2008; Chen, Wu et al. 2009;
Kim, Jeong et al. 2009; Kim, Ou et al. 2009; Nam, McGinn et al. 2010; Namgung,
Brumbach et al. 2010; Kim, Lee et al. 2012; Lee, Nam et al. 2012). Lee and
coworkers have demonstrated that cross-linking of low-molecular-weight PEI with
reducible cross-linkers such as dithiobis(succinimidylpropionate) (DSP) and
dimethyl

3,3’-dithiobispropionimidate

(DTBP)

could

mediate

significantly

improved gene delivery to Chinese hamster ovary (CHO) cells (Gosselin, Guo et
al. 2001). Similar approaches to crosslinking PEI with different linkers (e.g.,
dithiodipropionic acid) or via different chemical reactions (Michael addition
reaction, ring-opening reaction) have also been extensively explored. These
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cross-linked bioreducible PEI all showed improved safety profile and enhanced
transgene expression compared with the standard 25 kDa PEI, indicating the
important role of reducible moieties in developing efficient and safe non-viral
gene delivery vectors (Yockman, Maheshwari et al. 2003; Buehler, van
Zandvoort et al. 2006; Neu, Sitterberg et al. 2006; Neu, Germershaus et al. 2007;
Sun, Zeng et al. 2008; Koo, Jin et al. 2010).

1.6 Conclusion
In the following chapters of this dissertation, I will present the most
important findings on the development of bioreducible polyplexes and study of
their physicochemical and biological properties. The effect of nucleic size on the
physicochemical properties and biological activity of redox-responsive polyplexes
is explored in Chapter 2. Chapter 3 focuses on incorporating hyaluronic acid into
the structure of bioreducible polyplexes to improve steric stability and to achieve
targeted delivery to CD44 expressing cancers. The last two chapters introduce
novel design concept of multifunctional bioreducible polyplexes suitable for
drug/gene combination therapies, with the additional option of PET imaging.
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CHAPTER 2
EFFECT OF NUCLEIC ACID SIZE ON PHYSICAL PROPERTIES AND
BIOLOGICAL ACTIVITIES OF BIOREDUCIBLE POLYPLEXES

Please note that the content of this chapter was published in the European
Journal of Pharmaceutical Sciences (Li, Manickam et al. 2012). As the first
author, I performed all the work in the paper except the polymer synthesis
(contributed by Dr. D. Manickam, the second author) and the measurement of
molecular weights of all the polymers using GPC (contributed by Dr. J. Chen, the
third author). All the authors agreed with including their work in this dissertation.

2.1 Introduction
Polyplexes

of

nucleic

acids

and

bioreducible

polycations

have

demonstrated promise as delivery vectors of a variety of potential nucleic acid
therapeutics (Rahbek, Howard et al. 2008; Manickam, Li et al. 2010; Namgung,
Brumbach et al. 2010). The bioreducible polyplexes take advantage of the strong
reducing intracellular environment in which the disulfide-containing polycations
are readily broken down by thiol-disulfide exchange reactions. The intracellular
degradation is then responsible for decreased toxicity of bioreducible polycations
and is often credited also with increased transfection activity of due to easier
DNA release. The reducing intracellular environment is primarily maintained by
small redox molecules like glutathione (GSH) either with or without the help of
redox enzymes (Gilbert 1997; Jiang, Fitzgerald et al. 1999; Donoghue and Hogg
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2002). Recent study has indicated that intracellular protein thiols (PSH) may
represent a pool of active reducing species that is even larger than that of GSH
(Hansen, Roth et al. 2009).
Improved transfection activity of bioreducible polyplexes is an almost
universal finding reported with various different types of bioreducible polycations,
including polypeptides, polymethacrylates, and poly(amido amine)s (PAA) (Chen,
Kim et al. 2006; Christensen, Chang et al. 2006; Lin, Zhong et al. 2006;
Manickam and Oupicky 2006; You, Manickam et al. 2007; Piest, Lin et al. 2008).
The increased transfection activity is believed to be the consequence of the
decreased affinity between DNA and the bioreducible polycations after their
intracellular degradation. The reduced affinity is expected to enhance
transcriptional availability of DNA due to faster and easier polyplex disassembly
(Read, Bremner et al. 2003; Christensen, Chang et al. 2006). This notion is
supported by at least some available evidence, which suggest that artificial
changes in intracellular GSH levels can change transfection activity of
bioreducible polyplexes, although the effect is often small. In general, increasing
intracellular GSH by incubation with a membrane-permeable derivative of GSH
leads to an increase in transfection of bioreducible polyplexes (Read, Bremner et
al. 2003; Christensen, Chang et al. 2006; Neu, Germershaus et al. 2007). Some
reports, however, found the opposite effect as increased GSH lowered
transfection (Read, Singh et al. 2005). Similar conflicting evidence is available
from studies in which intracellular GSH is depleted by inhibiting its de novo
synthesis. In most cases, a small decrease in transfection is observed after
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inhibiting GSH synthesis with inhibitor of γ-glutamylcysteine synthetase,
buthionine sulfoximine (Read, Bremner et al. 2003; Read, Singh et al. 2005;
Christensen, Chang et al. 2006; Neu, Germershaus et al. 2007; Manickam, Li et
al. 2010). The opposite effect of GSH inhibition on transfection of bioreducible
polyplexes was reported in a study that showed increased transfection after
inhibition of GSH biosynthesis (Hoon Jeong, Christensen et al. 2007). These
results suggest that the notion of a straightforward relationship between
intracellular reducing potential, enhanced disassembly, and transfection activity
of bioreducible polyplexes could be an oversimplified view.
This chapter focuses on how enhanced reductive disassembly affects
transfection activity of plasmid DNA and antisense oligonucleotides (AON)
polyplexes based on a series of bioreducible polycations with increasing content
of disulfide bonds. The hypothesis of this study is that the molecular weight of the
used nucleic acid would strongly influence activity of bioreducible polyplexes
because of the differences in binding affinity with polycations.

2.2 Materials and Methods
2.2.1 Materials
N,N’-hexamethylenebisacrylamide
cystaminebisacrylamide

(CBA)

were

(HMBA)
obtained

from

and
Polysciences,

N,N’Inc.

(Warrington, PA). 1-(2-Aminoethyl) piperazine (AEPZ) was obtained from Acros
Organics (Fisher Scientific, Pittsburgh, PA). Plasmid DNA, gWiz high-expression
luciferase (gWiz-Luc) containing luciferase reporter gene was from Aldevron
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(Fargo,

ND).

Luciferase

AACCGCTTCCCCGACTTCC-3')

antisense
and

oligonucleotides
its

scrambled

(AON)

(5'-

control

(5'-

CCAATGTCAAGCACTT CCGTT-3') with phosphorothioate linkages were
custom synthesized by Midland Certified Reagent Company (Midland, TX). 1,2Dioleoyl-3-trimethylammonium-propane chloride (DOTAP) was purchased from
Toronto Research Chemicals Inc. (North York, ON, Canada). YOYO®-1 iodide,
Dulbecco’s Modified Eagle Medium (DMEM), Dulbecco’s Phosphate Buffered
Saline (PBS), Fetal Bovine Serum (FBS) and non-essential amino acids (NEAA)
were from Invitrogen (Carlsbad, CA). All other reagents and chemicals were
obtained from Fisher Scientific or VWR International unless otherwise noted.

2.2.2 Synthesis and characterization of PAA
A series of five linear PAA containing different disulfide content was
synthesized by Michael addition of triamine AEPZ and different molar ratio of
reducible CBA and non-reducible HMBA (Scheme 1) following a published
method (Lin, Zhong et al. 2006; Manickam, Li et al. 2010). Calculated amounts of
HMBA, CBA and AEPZ were dissolved in methanol/water (7/3 v/v) and the
polymerization was allowed to proceed in the dark at 37 °C for 72 h to form the
linear polymers (Hong, You et al. 2007). The reaction mixtures were then diluted
with water, acidified to pH 4 with HCl, and purified using centrifugal membrane
filters (molecular weight cut-off 3 kDa). The concentrates were lyophilized and
the composition of the polymers was analyzed by 1H and 13C NMR. The following
CBA:HMBA molar ratios were used in the polymerization: 0:1, 1:3, 1:1, 3:1 and
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1:0, which resulted in

a series of PAA with CBA content of 0, 25, 50, 75 and

100 %. Weight- (Mw) and number- (Mn) average molecular weights of the
polymers were determined by GPC using Shimadzu LC-10ADVP liquid
chromatograph equipped with a multiangle light scattering detector and an
interferometric refractometer (Wyatt Technology, Santa Barbara, CA). Sodium
acetate (300 mM, pH 4.5) was used as an eluent at a flow rate of 1.0 mL/min and
temperature of 35 °C.

Scheme 1. Synthesis of PAA.
2.2.3 Ethidium bromide and OliGreen exclusion assay
The ability of PAA to condense DNA was determined by ethidium bromide
(EtBr) exclusion assay by measuring the changes in EtBr/DNA fluorescence.
DNA solution at a concentration of 20 µg/mL was mixed with EtBr (1 µg/mL),
fluorescence was measured and set to 100% using an excitation wavelength of
540 nm and an emission wavelength of 590 nm. Fluorescence readings were
taken following a stepwise addition of the polycation solution, and the
condensation curve for each polycation was constructed. The ability of PAA to
condense AON was determined in a similar way by measuring changes in
OliGreen/AON fluorescence, using 490 nm excitation and 520 nm emission.
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2.2.4 Preparation and characterization of DNA and AON polyplexes
gWiz-Luc DNA solution at a concentration 20 µg/mL was prepared in 30
mM sodium acetate buffer (pH 5.0). PAA/DNA polyplexes were formed by adding
predetermined volume of PAA to achieve the desired N/P ratio and mixed by
vigorous vortexing for 10 s. Polyplexes were further allowed to stand for 30 min
prior to use. AON polyplexes were prepared by following the same protocol,
except that AON was heat-denatured for 10 min at 65 °C and snap-cooled on ice
prior to dilution in the buffer. The determination of hydrodynamic diameters and
zeta potentials of both polyplexes was performed following previously published
method (Manickam, Bisht et al. 2005). Results were expressed as mean ±
standard deviation (S.D.) of 10 experimental runs each.

2.2.5 Agarose gel electrophoresis
Reduction-triggered disassembly of the polyplexes was examined by
agarose gel electrophoresis using a previously described protocol (Read,
Bremner et al. 2003). Briefly, DNA polyplexes were formed as described above
and incubated under indicated conditions. Samples were loaded onto a 0.8%
agarose gel containing 0.5 µg/mL EtBr and run for 75 min at 120 V in 0.5X
Tris/Borate/EDTA (TBE) running buffer. The gel was visualized under UV. AON
polyplexes were analyzed on a 2% agarose gel containing EtBr for 30 min at 80
V under conditions mentioned above.
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2.2.6 Cell culture
Mouse mammary carcinoma cell line D2F2 was a kind gift from Dr. WeiZen Wei, Karmanos Cancer Institute (Detroit, MI). The cells were maintained in
DMEM supplemented with 4 mM L-glutamine, 0.1 mM NEAA and 10% FBS at 37
°C in 5% CO2 atmosphere.

2.2.7 Transfection of DNA and AON polyplexes
All transfection experiments were conducted in 48-well plates during
logarithmic growth phase following a previously published protocol (Manickam, Li
et al. 2010). Cells were seeded at a density of 40,000 cells/well 24 h prior to
transfection. On a day of transfection, the cells were incubated with the
polyplexes (DNA dose: 0.4 µg/well) in 150 µL of serum-free media. After 3 h
incubation, polyplexes were completely removed and the cells were cultured in
complete culture medium for 24 h prior to measuring luciferase expression. The
medium was then discarded and the cells were lysed in 100 µL of 0.5x cell
culture lysis reagent buffer (Promega, Madison, WI) for 30 min. To measure the
luciferase content, 100 µL of 0.5 mM luciferin solution was automatically injected
into each well containing 20 µL of cell lysate and the luminescence was
integrated over 10 s using BioTek Synergy 2 Microplate Reader. Total cellular
protein in the cell lysate was determined by the bicinchoninic acid (BCA) protein
assay using calibration curve constructed with standard bovine serum albumin
solutions (Pierce, Rockford, IL). For cell surface thiol blocking, the cells were preincubated with 1 mM of DTNB in DMEM for 30 min. The DTNB solution was
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removed before conducting the transfection experiments as above. Transfection
activity was expressed as RLU/mg cellular protein ± S.D. of quadruplicate
samples. For AON transfections, the cells were transfected with 0.4 µg luciferase
DNA per well using DOTAP liposomes (N/P ratio 16) 24 h before transfected with
AON polyplexes (0.8 µg/well). The transfection efficiency was expressed as %
knock-down compared with control scrambled AON.

2.2.8 Cell uptake by flow cytometry
The cellular association of the fluorescently-labeled polyplexes was
measured using flow cytometry. Cells were plated in a 24-well plate 24 hours
before transfection. Polyplexes were formed using DNA labeled with YOYO-1 by
mixing at a ratio of 1 dye molecule per 100 bp of DNA. After 3 h of transfection,
cells were washed with PBS, detached, and resuspended in 200 µL PBS. 10,000
events per sample were counted on FACS. Histogram plots were constructed
using the CellQuest software. The mean fluorescence intensity from each sample
was obtained and the cellular uptake was quantified as average mean
fluorescence intensity ± SD of triplicate samples.

2.2.9 Kinetics of intracellular plasmid DNA clearance
Intracellular content of the gWiz-Luc plasmid DNA at different time points
after incubation was measured using real-time PCR (RT-PCR, ABI Prism®
7300). The following probe and primers were designed in BioSearch online
RealTimeDesign™ software: FAM-BHQ probe TCAGGATTACAAGATTCAAAGT
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GCGCT, forward primer GAAGAGCTGTTTCTGAGG, reverse primer CGAAGAA
GGAGAATAGGGT. The 18S rDNA probe and the master mix were purchased
from Eurogentec (San Diego, CA). Cells were incubated with DNA polyplexes for
3 h under conditions used in the transfection studies. At predetermined times
after incubation, the cells were washed twice with warm PBS and lysed with 100
µL of RT-PCR lysis buffer for 1 h at 37 °C. The lysate (25 µL) was transferred to
a deep-well plate and diluted with 475 µL of sterile water. The lysate was then
incubated for 15 min in 95 °C water bath to inactivate proteinase K. During the
RT-PCR cycle, 5 µL of DNA template, 75 nM probe and 600 nM primer pairs
were added. To determine 18S rRNA, 125 nM probe and 600 nM primer pairs
were added to the template. The PCR cycle was run for 2 min at 50 °C, 10 min at
95 °C, 40 cycles for 15 s at 95 °C, and 1 min at 60 °C. The number of plasmid
DNA copies was normalized to 18S rRNA and calculated as 2n, where n = (Ct18S
rRNA –

Ctluc).

2.2.10 Statistical analysis
Significant differences between two groups were determined using
Student’s t-test and differences among multiple groups were determined using
ANalysis Of VAriance (ANOVA). A p-value < 0.05 was considered statistically
significant in all cases.

2.3 Results and Discussion
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Bioreducible polycations have been widely investigated as delivery vectors
of nucleic acids because of their favorable toxicity profile and the possibility to
preferentially restrict release of the delivered nucleic acids to intracellular
locations such as cytoplasm and nucleus. Both the decreased toxicity and
controlled intracellular release are believed to be caused by degradation of
disulfide-containing polycations mediated by reduced GSH abundantly present in
the cytoplasm (Vercauteren, Piest et al. 2011). However, while reduced toxicity of
bioreducible polycations is a nearly-universal finding, improved transfection
activity of bioreducible polyplexes is not. This raises a question about the
importance of the presumed increased intracellular disassembly of bioreducible
polyplexes for transfection. The goal of this study was to systematically
investigate how decreasing stability against disassembly affects transfection
activity of plasmid DNA and AON polyplexes.

2.3.1 Synthesis and characterization of linear PAA with different disulfide content
In order to achieve the goal of this study, five polycations with similar
molecular weights and with increasing disulfide content were synthesized. The
disulfide content was controlled by the feeding molar ratio of reducible (CBA) and
non-reducible (HMBA) bisacrylamide monomers. The weight-average molecular
weight (Mw) and polydispersity index (PDI) of the five synthesized PAAs were
determined by GPC and are listed in Table 1. The synthesized PAA had similar
Mw ranging from 5,700 to 7,400 and polydispersity indices ranging from 1.1 to
2.0. The ratio of CBA-to-HMBA in the polymers was nearly identical to the
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feeding ratio, suggesting similar reactivity of the two bisacrylamides. PAA
polymer was chosen based on a piperazine triamine AEPZ because of previous
reports that confirm its good transfection activity (Lin, Zhong et al. 2006;
Blacklock, You et al. 2009; Manickam, Li et al. 2010). Although AEPZ may
function potentially as a trifunctional monomer in the polymerization, the distinct
reactivity of the AEPZ amines allows synthesis of linear polymers by a simple
control of reaction stoichiometry (Wang, Liu et al. 2005; Lin, Zhong et al. 2006).
The absence of a branched structure of AEPZ after its reaction with two
equivalents of acrylamide was observed, indicating that the acyclic secondary
amine formed after addition of a primary amine to AEPZ has a much lower
reactivity than the original cyclic secondary amine and primary amine in AEPZ.
Thus linear structure was preferentially formed due to the order of different
reactivity of the amines: secondary amine (original) > primary amine > secondary
amine (formed).

Table 1. Molecular weights of PAA.
Polymer
PAA-0
PAA-25
PAA-50
PAA-75
PAA-100
*

Reducible
content (%)*
0
25
50
75
100

Mw

Mw /Mn

7,400
7,100
6,200
5,700
5,800

1.1
1.1
1.2
1.9
2.0

relative content of CBA in PA: 100*[CBA]/([CBA]+[HMBA])

2.3.2 Effect of nucleic acid size on binding of PAA and nucleic acids
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OliGreen is an ultra-sensitive fluorescent nucleic acid dye that binds
oligonucleotides and single-stranded DNA. Its fluorescence corresponds to free
unbound

oligonucleotides

in

solution.

The

fluorescence

intensity

of

OliGreen/AON decreased linearly with increasing N/P ratio (Figure 3a). Full
complexation of AON was achieved with all five PAA at N/P > 0.8 as indicated by
no further fluorescence decrease beyond this ratio. EtBr exclusion assay was
carried out in analogous manner to test the ability of PAA to condense plasmid
DNA (Figure 3b). The condensation curves for all PAA displayed typical
sigmoidal shape characteristic of DNA condensation. N/P ratios above 1.8 were
required to fully condense the DNA. Figure 3 documents that there were no
significant differences in DNA and AON complexation ability among the five PAA,
suggesting that the presence of disulfide bonds in the polycations does not affect
their binding to nucleic acids.

Figure 3. Nucleic acid condensation by PAA. (a) OliGreen exclusion assay to
assess AON condensation and (b) EtBr exclusion assay to assess DNA
condensation.
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2.3.3 Effect of nucleic acid size on particle size and zeta-potential of PAA
polyplexes
Size and zeta potential directly influence cellular uptake and transfection
activity of polyplexes. Hydrodynamic size and zeta-potential of polyplexes were
measured before every in vitro test. Polyplexes were formulated with about a 4fold excess of polycation relative to the minimum amount needed to fully
condense the corresponding nucleic acid as determined from Figure 3. Thus,
DNA polyplexes were prepared at N/P = 8 and AON polyplexes at N/P = 4. As
shown in Table 2, the sizes of PAA/DNA polyplexes showed no dependence on
the disulfide content in PAA as they all fell into a narrow range of 96-102 nm. The
sizes of all PAA/AON polyplexes (average size 64 ± 11 nm) were significantly
smaller than the sizes of DNA polyplexes (average size 100 ± 5 nm), with the
smallest size (53 nm) observed for polyplexes formulated with PAA with the
highest disulfide content (PAA-100). All polyplexes, regardless of the type of
nucleic acid, were highly positively charged with zeta potential ranging from 22 to
37 mV. The average zeta potential of DNA polyplexes (30 mV) was higher than
the average zeta potential of AON polyplexes (26 mV). The independence of the
physicochemical properties of polyplexes on disulfide content was important
because it allowed us to minimize, although not fully eliminate, any potential
confounding effects on the studied biological behavior of the polyplexes that were
not directly related to the presence of disulfides.
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Table 2. Hydrodynamic size and zeta potential of PAA polyplexes.
DNA polyplexesa
Polymer

Size
(nm)

PAA-0
PAA-25
PAA-50
PAA-75
PAA-100

96 ± 2
98 ± 10
107 ± 1
96 ± 5
102 ± 1

a
b

Zetapotential
(mV)
26 ± 2
30 ± 1
27 ± 1
28 ± 1
37 ± 1

AON polyplexesb
Size
(nm)
66 ± 3
74 ± 2
75 ± 2
53 ± 2
53 ± 1

Zetapotential
(mV)
27 ± 2
22 ± 2
26 ± 1
29 ± 4
25 ± 5

prepared at N/P ratio 8
prepared at N/P ratio 4.

2.3.4 Effect of nucleic acid size on reduction-triggered disassembly of PAA
polyplexes
Reduction-triggered disassembly of the PAA polyplexes was evaluated
from differences in DNA and AON release patterns in the oxidizing and reducing
conditions using agarose gel electrophoresis (Figure 4). In addition to treatment
with 20 mM GSH, the polyplexes were also incubated with 0.75 M NaCl to further
facilitate disassembly and release of the nucleic acids. Incubation with 20 mM
GSH resulted in loosening and partial dissociation of the polyplexes, documented
by a partial release of both AON and DNA. Release behavior of polyplexes of
both nucleic acids showed a clear dependence on the disulfide content in PAA.
Partial AON release was observed at lower disulfide content in PAA (PAA-50)
than DNA release (PAA-75). Addition of NaCl enhanced not only the amount of
released nucleic acid but also resulted in free nucleic acids observed at lower
disulfide contents in PAA. Despite the combined action of GSH and NaCl, neither
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DNA nor AON were released from non-reducible PAA-0 polyplexes. Quantitative
analysis of the release of AON and DNA from PAA polyplexes incubated with 20
mM GSH and 0.75 M NaCl is shown in Figure 5. Data for both AON and DNA
polyplexes confirm that increasing the disulfide content leads to increased
amount of released nucleic acid. PAA-100 polyplexes of DNA were more
susceptible to the GSH/NaCl treatment than AON polyplexes, with almost 80% of
released DNA vs. 68% of released AON. Overall, both types of nucleic acids
showed similar release behavior. Interestingly, despite greatly different sizes of
AON and plasmid DNA, only a small effect of the nucleic acid size on the
disassembly behavior was observed.

Figure 4. Reduction-triggered release of AON (top) and plasmid DNA (bottom)
from PAA polyplexes. Polyplexes were prepared at N/P 4 (AON) and N/P 8
(DNA) and incubated with 20 mM GSH and 0.75 M NaCl.
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Figure 5. Quantification of the reduction-triggered release of AON (a) and
plasmid DNA (b) from PAA polyplexes. Polyplexes prepared at N/P 4 (AON) and
N/P 8 (DNA) were incubated with 20 mM GSH and 0.75 M NaCl and the amount
of released nucleic acid quantified by analyzing the fluorescence intensity of the
bands. % nucleic acid release equals the ratio of fluorescence intensity of
released AON or DNA band to the fluorescence intensity of the free AON or
DNA.
2.3.5 Effect of nucleic acid size on stability of PAA polyplexes against
polyelectrolyte exchange
It is hypothesized that the intracellular disassembly of bioreducible
polyplexes is a result of the combined effect of reduction and polyelectrolyte
exchange reactions with intracellular polyelectrolytes (proteins, nucleic acids).
Exchange reactions with negatively charged intracellular proteins, including actin
and tubulin, have been shown to be responsible for intracellular release of
plasmid DNA from PEI polyplexes (Iida, Mori et al. 2007). The effect of PAA
disulfide reduction on the resistance of the polyplexes against polyelectrolyte
exchange with a competing polyanion heparin was evaluated by agarose gel
electrophoresis (Figure 6). In oxidizing conditions, DNA polyplexes show first
signs of destabilization at a heparin concentration of 30 µg/ml while AON
polyplexes start to disassemble at a heparin concentration of 20 µg/ml. Similar
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behavior was observed for both AON and DNA polyplexes regardless of disulfide
content. In reducing conditions of 20 mM GSH, the threshold heparin
concentration required to destabilize the polyplexes and release the nucleic acids
decreased with increasing disulfide content in PAA. No significant differences in
susceptibility to heparin-induced DNA and AON release were observed in the
absence of GSH, confirming similar DNA and AON binding affinities of all PAA. It
is worth pointing out the difference in the release pattern of AON and DNA that
reflects the different mechanism of condensation of the two types of nucleic acids
(Figure 3) (Wan, You et al. 2009). While AON is released gradually with
increasing heparin concentration, DNA is released in a more abrupt manner at a
certain critical concentration of heparin. GSH treatment makes both AON and
DNA polyplexes more susceptible to exchange with heparin.

Figure 6. Effect of disulfide reduction on susceptibility of PAA polyplexes to
polyelectrolyte exchange reactions. AON (left) and plasmid DNA (right)
polyplexes of PAA were treated with increasing concentration of heparin and/or
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20 mM GSH. AON and DNA release were analyzed by agarose gel
electrophoresis.
2.3.6 Effect of nucleic acid size on stability of PAA polyplexes against serum
Systemic delivery of polyplexes through intravenous injection requires that
they are stable in the presence of serum. The stability of both DNA and AON
polyplexes in the presence of serum was investigated using agarose gel
electrophoresis (Figure 7). No DNA or AON release was observed after
incubation with serum, indicating no significant cleavage of the disulfide bonds.
By contrast, free DNA and AON bind with serum components as indicated by a
smear on the gel (Figure 7, lane 5). Although no free nucleic acid was observed,
the increased fluorescence intensity in the wells in the presence of serum
suggested that interactions with serum components result in some loosening and
structural changes of the polyplexes that facilitate binding of EtBr.

Figure 7. Effect of serum on stability of AON and DNA polyplexes. PAA
polyplexes, free nucleic acids (NA) (AON, DNA), and RPMI medium were
incubated with (+) or without (-) 10% FBS and the presence/content of free
nucleic acids was analyzed by agarose gel electrophoresis.
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2.3.7 Effect of nucleic acid size on transfection activity of PAA polyplexes
Having established that both AON and DNA polyplexes display a range of
disulfide-dependent differences in their sensitivity to disassembly, we have
evaluated how such differences affect transfection activity. The effect of disulfide
content on transfection activity of the AON and DNA polyplexes was investigated
in D2F2 murine mammary carcinoma cells (Figure 8). All PAA/AON polyplexes
showed similar knock-down levels with no statistically significant (one-way
ANOVA) effect of PAA disulfide content observed (Figure 8a). In contrast,
transfection activity of PAA/DNA polyplexes increased with increasing disulfide
content in PAA (Figure 8b), although the observed trend was not statistically
significant in linear regression analysis (P > 0.05 for slope being non-zero). Oneway ANOVA with Bonferroni multiple comparison test, however, revealed that
PAA-100 polyplexes had significantly higher transfection activity than all the other
polyplexes with lower disulfide content. PAA-100 polyplexes showed a 152-fold
higher transfection than PAA-0/DNA and a 6-fold higher transfection compared
with control PEI/DNA polyplexes. The results show that despite the similarities in
the disassembly behavior, bioreducible PAA only enhanced transfection of DNA,
while providing no benefits for AON. The pattern of DNA transfection
dependence on disulfide content in PAA was similar to what was reported for the
same PAA previously (Lin, Zhong et al. 2006). The results clearly show that
intracellular degradation of PAA plays no significant role in AON delivery and
indirectly suggest that disassembly is not a barrier to effective AON delivery by
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polyplexes.

Figure 8. Effect of disulfide content on transfection activity of PAA polyplexes.
D2F2 cells were transfected with (a) anti-luciferase AON polyplexes and (b)
luciferase DNA polyplexes. Results are expressed as % knock-down of luciferase
expression and RLU/mg protein, respectively. (mean ± S.D., n = 4)
2.3.8 Cell uptake of PAA/DNA polyplexes
Because no effect of the presence of disulfide bonds on AON transfection
was observed, elucidating the reasons for increased DNA transfection was
further studied. The cellular uptake of PAA/DNA polyplexes was measured
(Figure 9) at the end of the 3 h incubation period by quantifying the fluorescence
intensity of polyplexes formulated with DNA that was non-covalently labeled with
YOYO-1. The results show about 2-fold higher DNA uptake with PAA-100/DNA
polyplexes when compared with the other four PAA/DNA polyplexes.
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Figure 9. Effect of disulfide content on cell uptake of PAA/DNA polyplexes. D2F2
cell uptake of DNA labeled with YOYO-1 was measured after 3 h incubation with
PAA polyplexes using flow cytometry. Cell uptake is shown as mean relative
fluorescence intensity (RFI) ± S.D. (n = 6)
2.3.9 Intracellular clearance of pDNA after transfection with PAA polyplexes
Cell uptake shown in Figure 9 is only a snapshot at a single time point and
one that is unable to distinguish between intact (viable) and degraded (nonviable)
DNA. The rate of intracellular plasmid DNA clearance is also an important
determinant of transfection efficiency. Intracellular clearance of plasmid DNA has
been connected to disassembly rates of polyplexes and thus the kinetics of
intracellular clearance of plasmid DNA delivered by PAA was further investigated
(Figure 10). D2F2 cells were incubated with the polyplexes for 3 h and then
harvested at 0, 6, 12, 18, 24, and 48 h after the incubation. The amount of
plasmid DNA in whole cell lysate at the different time points was quantified with
RT-PCR. The results from this independent experiment confirmed findings from
Figure 9 that PAA-100/DNA polyplexes exhibit the highest initial cell uptake. The
results show that intracellular plasmid DNA content declined rapidly in the first 18
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h after incubation. Analysis of the data using first-order kinetics (ln[DNA] vs. time)
revealed no statistically significant trend as the rate constants of the plasmid
DNA clearance were similar regardless of the disulfide content in PAA.

Figure 10. Intracellular clearance of plasmid DNA delivered by PAA. D2F2 cells
were incubated with PAA/DNA polyplexes for 3 h. The cells were then harvested
and lysed at different time points post-incubation and luciferase DNA was
quantified and normalized to 18S rDNA by RT-PCR. (mean number of plasmid
DNA copies per 18S rDNA ± S.D., n = 4)
2.3.10 Influence of cell surface thiols on transfection activity of PAA/DNA
polyplexes
Since all the PAA/DNA polyplexes had similar physicochemical properties,
we hypothesized that thiol-disulfide exchange between the disulfides in
PAA/DNA polyplexes and reducing thiols in plasma membrane proteins could be
responsible for the increased uptake and transfection of bioreducible DNA
polyplexes. It has been reported that similar thiol-disulfide reactions on the cell
surface are required for cell entry of viruses like HIV and play a role in cell entry
of disulfide-containing peptides (Ryser, Levy et al. 1994; Markovic, Stantchev et
al. 2004; Jain, McGinnes et al. 2007; Aubry, Burlina et al. 2009). An early study
also suggested the reducing cell surface thiols are involved in cell uptake of
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bioreducible lipoplexes (Kichler, Remy et al. 1995). To further investigate the role
of PAA disulfide bonds in facilitating enhanced cell uptake and transfection
activity, the effect of plasma membrane protein thiols on transfection activity of
PAA polyplexes was studied (Figure 11). D2F2 cells were treated for 30 min
before transfection with cell impermeable nonspecific thiol blocker DTNB to block
external plasma membrane protein thiols. The effect of the thiol blocking on
transfection activity was then studied and the results were expressed as a
relative transfection, calculated as the ratio of luciferase expression in DTNBtreated vs. untreated cells. As shown in Figure 11, non-reducible polyplexes
(PAA-0) showed a 27% decrease in transfection after DTNB pretreatment (i.e.,
relative transfection 0.73). In contrast, all bioreducible PAA polyplexes exhibited
significant decrease in transfection. Polyplexes prepared with PAA-100 exhibited
the largest decrease (97.6%) after blocking the plasma membrane surface thiols.
As a result of the DTNB treatment, absolute levels of luciferase expression of all
five PAA/DNA polyplexes was similar regardless of the disulfide content in PAA.
Hence by blocking the cellular surface thiols, the transfection of disulfidecontaining polyplexes is decreased to a much larger extent than transfection of
non-reducible PAA polyplexes. In fact, blocking the surface thiols resulted in the
bioreducible polyplexes losing their transfection advantage as all five tested
PAA/DNA polyplexes exhibited similar levels of transfection in cells with the cell
surface thiols blocked. This evidence suggests that the thiol-disulfide reactions at
the cell membrane play a key role in enhancing transfection of the bioreducible
PAA/DNA polyplexes.
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Figure 11. Effect of cell surface thiols on inhibition of transfection of PAA/DNA
polyplexes. D2F2 cells were pretreated with 1 mM DTNB for 30 min before
transfection. The data represent relative transfection in RLU/mg protein in cells
pretreated with DTNB vs. untreated cells.
2.4 Conclusions
Bioreducible polyplexes have shown to be promising vectors for delivery
of nucleic acids due to low toxicity and favorable transfection activity. The often
improved transfection is usually explained by enhanced intracellular reductive
disassembly of the polyplexes. This study evaluated the effect of enhanced
reductive disassembly on transfection activity of plasmid DNA and AON
polyplexes based on a series of bioreducible poly(amido amine)s (PAA). The
presence of disulfide bonds in PAA had no effect on nucleic acid binding,
hydrodynamic size and zeta potential of polyplexes. Increasing the disulfide
content in PAA increased susceptibility to reduction-triggered DNA and AON
release from the polyplexes. Increasing the disulfide content in PAA increased
DNA transfection but had no effect on AON transfection. Plasma membrane
protein thiols played a key role in the observed enhancement of DNA
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transfection. The presence of disulfide bonds in PAA had no significant effect on
the rate of intracellular DNA clearance, suggesting that enhanced intracellular
disassembly of the bioreducible polyplexes is not a major contributing factor to
the improved transfection activity.
As illustrated in this chapter, the advantages of bioreducible polyplexes
are much more pronounced when delivering plasmid DNA than when delivering
small nucleic acids. The following chapters will focus on improving plasmid DNA
delivery by various methods including modifying the system with cancer targeting
moiety (Chapter 3), developing multifunctional delivery system for gene delivery
and PET imaging (Chapter 4) and combined drug/gene delivery (Chapter 5).
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CHAPTER 3
CD44-TARGETED BIOREDUCIBLE POLYPLEXES FOR GENE DELIVERY

3.1 Introduction
The primary challenge for non-viral cancer gene therapy is to safely
deliver an effective dose of therapeutic gene to the desired tumor tissue. Despite
many advantages of non-viral vectors over viral vectors low efficiency and lack of
targeting ability remain to be major problems faced by non-viral gene delivery
vectors (Lo, Day et al. 2005; Yamamoto and Curiel 2005; Kaneda and Tabata
2006; Alexandrova 2009). Bioreducible polyplexes with the capability to respond
to redox potential gradients across the cell membrane demonstrated promise as
attractive non-viral candidates for cancer gene therapy. Incorporating disulfide
bonds into the structure of polycations allows polyplexes to undergo intracellular
GSH-mediated reduction which leads to rapid intracellular release of the
delivered nucleic acids (Gilbert 1997; Jiang, Fitzgerald et al. 1999; Donoghue
and Hogg 2002). The improved disassembly of the polyplexes ultimately
enhances the transfection efficiency and decreases cytotoxicity of the polyplexes
(Read, Singh et al. 2005; You, Manickam et al. 2007; Manickam, Hirata et al.
2008; Chen, Wu et al. 2009; Zhou, Wu et al. 2009). Evidence shows that many
types of cancer, including melanoma exhibit significantly elevated GSH levels,
which is often correlated with higher metastatic potential. The elevated GSH
levels in tumor cells compared with most normal tissues might be
advantageously exploited to improve activity of the redox-responsive polyplexes.
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Invasive cancers have the capability to metastasize from the primary
tumor site through the vasculature or lymphatic system to distant organs. The
process greatly depends on the ability of cancer cells to attach to and invade
through the extracellular matrix. CD44 is a cell-surface glycoprotein that functions
as a signaling transmitter that controls cellular adhesion, migration, and invasion.
All these processes are involved in cancer metastasis, which makes CD44 highly
relevant to cancer cell invasion and metastasis (Matsumura and Tarin 1992;
Dietrich, Tanczos et al. 1997; Sheridan, Kishimoto et al. 2006; Ouhtit, Elmageed
et al. 2007). Overexpression of CD44 is often found in many types of metastatic
cancer cells such as breast cancer, lung carcinoma and melanoma. There is
increasing evidence that cancer cells that overexpress CD44 are more metastatic
than cells with low CD44 levels (Naor, Nedvetzki et al. 2002; Al-Hajj, Wicha et al.
2003; Hill, McFarlane et al. 2006). In addition to the importance of CD44 as a
target in metastatic cancers, growing evidence has linked CD44 with the cancer
stem cell hypothesis (Al-Hajj, Wicha et al. 2003; Collins, Berry et al. 2005; Li,
Heidt et al. 2007; Prince, Sivanandan et al. 2007). The validity of CD44 as a
target in human cancers has been confirmed in clinical trials using anti-CD44
antibodies for the treatment of CD44-expressing tumors (Colnot, Ossenkoppele
et al. 2002; Borjesson, Postema et al. 2003; Colnot, Roos et al. 2003; Koppe,
Schaijk et al. 2004; Tijink, Buter et al. 2006; Rupp, Schoendorf-Holland et al.
2007; Sauter, Kloft et al. 2007).
CD44 is a receptor for hyaluronic acid (HA), which is one of several
nonsulfated glycosaminoglycan components found in the extracellular matrix. HA
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plays an important role, through CD44, in regulating cell adhesion and motility
and mediating cell proliferation and differentiation (Entwistle, Hall et al. 1996;
Collis, Hall et al. 1998). HA is a water soluble, non-immunogenic linear
polysaccharide consisting of alternating D-glucoronic acid and N-acetyl-Dglucosamine units with a molecular weight ranging from 1 to 10,000 kDa
(Scheme 2). HA has been utilized directly as a drug carrier that can potentially
target CD44-overexpressing cancers. Since HA contains multiple functional
groups available for conjugation, it has also been investigated as a targeting
moiety and used to modify nanocarriers, such as liposomes and polyplexes
(Pouyani and Prestwich 1994; Luo and Prestwich 1999; Luo, Ziebell et al. 2000;
Eliaz and Szoka 2001; Eliaz, Nir et al. 2004; Peer and Margalit 2004; Peer and
Margalit 2004; Lee, Mok et al. 2007; Hornof, de la Fuente et al. 2008; Jiang, Park
et al. 2008; Lee, Lee et al. 2008; Lee, Ahn et al. 2009; Surace, Arpicco et al.
2009). Although CD44 is also found expressed in normal cells, selective targeting
to tumors is still possible because HA binding is greatly affected by posttranslational modifications of CD44 (Lesley, English et al. 2000; Lesley, Hascall
et al. 2000; Naor, Wallach-Dayan et al. 2008). For example, B cells express
CD44 but they do not bind HA until the CD44 is deglycosylated upon B cell
activation (Hathcock, Hirano et al. 1993; Katoh, Zheng et al. 1995; Skelton, Zeng
et al. 1998). In addition, solid tumors often exhibit a phenomenon called
enhanced permeability and retention (EPR) effect, which could be used for
passive targeting. This allows macromolecules and nanoparticles to preferentially
accumulate within tumors due to leaky tumor vasculature and limited lymphatic
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clearance (Maeda, Seymour et al. 1992; Hobbs, Monsky et al. 1998). In addition,
HA can function not only as a targeting ligand but also as a hydrophilic protective
shell promoting extended plasma circulation (Peer and Margalit 2004; Peer and
Margalit 2004).

Scheme 2. Chemical structure of HA.
The molecular weight of HA has been reported to affect its targeting
property and stabilization ability (Prestwich, Marecak et al. 1998; Girotto, Urbani
et al. 2003; Jiang, Park et al. 2008; Surace, Arpicco et al. 2009). High-molecularweight HA was shown to contribute to improved steric stability of nanoparticles
and liposomes. However, it tends to be more easily cleared from systemic
circulation by the liver membrane-bound HA receptor for endocytosis (HARE)
(Zhou, McGary et al. 2003). Hence, for the purpose of our study we will use lowand medium- (6.4 kDa and 59 KDa) molecular-weight HA to achieve CD44
targeting while avoiding rapid clearance by the liver HARE.
Recent studies from our laboratory have shown improved transfection
efficiency and low toxicity of a type of bioreducible hyperbranched poly(amido
amine)s (RHB) in vitro due to the high intracellular GSH level of cancer cells
(Chen, Wu et al. 2009). The hypothesis of this chapter is that low and medium
molecular weight HA will stabilize the bioreducible polyplexes and enable
targeting to the CD44-positive tumor cells. Three different approaches will be
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applied to modify RHB polyplexes with HA: (i) Non-covalent stabilization of
RHB/DNA polyplex by electrostatic deposition of HA layer on the surface; (ii)
Post-grafting of HA to preformed RHB/DNA polyplexes by covalent conjugation
using N-hydroxysuccinimidyl ester of HA (HA-NHS); and (iii) Preparation of graft
copolymers of HA and RHB and their use for the formation of DNA polyplexes.
The effect of the molecular weight and method of HA modification will be studied.

3.2 Materials and Methods
3.2.1 Materials
N,N’-cystaminebisacrylamide (CBA) was obtained from Polysciences, Inc.
(Warrington, PA). HA was from Lifecore Biomedical, Inc. (Chaska, MN). Plasmid
DNA, gWiz high-expression luciferase (gWiz-Luc) containing luciferase reporter
gene was from Aldevron (Fargo, ND). YOYO®-1 iodide was from Invitrogen
(Carlsbad, CA). All the anti-mouse CD44 and control antibodies were from
Biolegend (San Diego, CA). Dulbecco’s Modified Eagle Medium (DMEM),
Dulbecco’s Phosphate Buffered Saline (PBS), Fetal Bovine Serum (FBS) were
from Fisher Scientific. All other reagents and chemicals were obtained from
Fisher Scientific or VWR International unless otherwise noted.

3.2.2 Cell culture
Murine melanoma cell line B16F10 was purchased from ATCC
(Manassas, VA). B16F10 cells were maintained in DMEM media supplemented
with 10% FBS and cultured at 37 °C in 5% CO2 atmosphere.
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3.2.3 Flow Cytometry
The overexpression of CD44 on B16F10 cells and cellular association of
the FITC-labeled HA were confirmed using flow cytometry. Cells were plated in a
24-well plate 24 hours before. Cells were detached from the plates by nonenzymatic cell dissociation solution CellstripperTM and incubated with FITCconjugated anti-CD44 antibody or FITC-conjugated HA for 30 min on ice before
complete wash with PBS and counting by flow cytometry. Histogram plots were
constructed using the CellQuest software. The mean fluorescence intensity from
each sample was obtained and the cellular uptake was quantified as average
mean fluorescence intensity ± SD of triplicate samples.

3.2.5 Synthesis of RHB, HA-NHS, and RHB-HA
RHB polymers were synthesized Michael addition reaction of equal molar
ratio of CBA and dimethyldipropylenetriamine (DMDPTA) at 50 °C in
methanol/water (v/v 8/2) mixture following our previously published protocol
(Chen, Wu et al. 2009) (Scheme 3). The synthesis of RHB for HA conjugation
was modified by replacing 10% of DMDPTA with the same molar amount of NBoc-ethylenediamine to introduce primary amines. After isolation of the
copolymer, the Boc groups were removed by treatment with a mixture of
trifluoroacetic acid: triisobutylsilane: H2O=95: 2.5: 2.5, v/v (Brumbach, Lin et al.
2010), resulting in RHB with primary amines available for reaction with HA-NHS.
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Any residual solvents were removed by extensive dialysis followed by
lyophilization.

Scheme 3. Synthetic scheme of RHB, X=H or polymer chain.
The sodium salt of HA (both 6K and 60K) was converted to a
tetrabutylammonium (TBA) salt by acidic ion exchange (room temperature, 8 h)
with Dowex 50 W × 8–200 resin. Based on a published method (Luo and
Prestwich 2001), active N-hydroxysuccinimidyl ester of HA (HA-NHS) was then
synthesized by reaction with N-hydroxysuccinimidyl diphenylphosphate (SDPP)
with HA.TBA. The resulting HA-NHS was isolated by precipitation in hexane,
washed with excess acetone and finally dried under vacuum.

Scheme 4. Synthesis of the active NHS ester of HA.
The synthesis of RHB-HA copolymers was conducted by stirring HA-NHS
(dissolved in anhydrous DMSO) and RHB (w/w 1) in 0.1 M borate buffer (pH 8.5)
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with 0.15 M NaCl for 24 h. RHB-HA was then purified and isolated by dialysis
and lyophilization.

3.2.6 Preparation of HA-containing RHB polyplexes
gWiz-Luc DNA solution at a concentration 20 µg/mL was prepared in 10
mM HEPES buffer (pH 7.4). RHB-6HA and RHB-60HA DNA polyplexes were
formed by adding predetermined volume of HA-RHB copolymer to achieve the
desired w/w ratio and mixed by vigorous vortexing for 10 s. Polyplexes were
further allowed to stand for 30 min prior to use. Electrostatically stabilized
RHB/DNA polyplexes (denoted as pp/6HA and pp/60HA) were prepared by
adsorbing a layer of HA (6kDa or 60kDa) on the surface by adding a
predetermined amount of HA to preformed RHB/DNA polyplexes and allowing
the mixture to stand for 1 h. Post-grafted polyplexes (denoted as pp-6HA and pp60HA) were prepared by adding predetermined amount of HA-NHS to preformed
RHB/DNA polyplexes and letting the mixture to react for 4 h. The determination
of hydrodynamic diameters and zeta potentials of polyplexes was performed by
Dynamic Light Scattering (DLS). Results were expressed as mean ± standard
deviation (S.D.) of 3-10 experimental runs.

3.2.7 Gel electrophoresis
The stabilization of the polyplexes against disassembly induced by serum
and heparin was examined by agarose gel electrophoresis using previously
published protocol (Li, Manickam et al. 2012). Briefly, gWiz-Luc DNA polyplexes
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were incubated under indicated conditions with heparin or serum at 37 °C for 1 h.
Samples were then loaded onto a 0.8% agarose gel containing 0.5 µg/mL EtBr
and run for 75 min at 120 V in 0.5x Tris/Borate/EDTA (TBE) running buffer. The
gel was then visualized under UV.

3.2.8 Cell uptake
The cellular association of the fluorescently-labeled polyplexes was
measured using fluorescent microplate reader. B16F10 cells were plated in a 96well black plate with optical bottom 24 hours before. DNA was labeled with
YOYO-1 by mixing at a ratio of 1 dye molecule per 100 bp of DNA and used to
prepare polyplexes as above. After 4 h of incubation with the polyplexes, the
cells were washed with PBS and the fluorescence was measured by Synergy 2
Microplate Reader (BioTek, VT). The mean fluorescence intensity from each
sample was obtained and the cellular uptake was quantified as average mean
fluorescent units (RFU) ± SD (n=4).

3.2.9 Luciferase transfection
All transfection experiments were conducted in 48-well plates with cells at
logarithmic growth phase following a previously published protocol (Read, Singh
et al. 2005). Cells were seeded at a density of 40,000 cells/well 24 h prior to
transfection. On the day of transfection, cells were incubated with the polyplexes
(DNA conc. 2.35 µg/mL) in 170 µL of serum-free or 10% FBS-containing media.
After 4 h incubation, polyplexes were completely removed and the cells were
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maintained in complete culture medium for 24 h prior to measuring luciferase
expression. The medium was discarded and the cells were lysed in 100 µL of
0.5x cell culture lysis reagent buffer (Promega, Madison, WI) for 30 min. To
measure the luciferase content, 100 µL of 0.5 mM luciferin solution was
automatically injected into each well of 20 µL of cell lysate and the luminescence
was integrated over 10 s using Synergy 2 Microplate Reader (BioTek, VT). Total
cellular protein in the cell lysate was determined by the Bicinchoninic acid (BCA)
protein assay using calibration curve constructed with standard bovine serum
albumin solutions (Pierce, Rockford, IL). Transfection activity was expressed as
relative light units (RLU)/mg cellular protein ± SD of quadruplicate samples.

3.3 Results and Discussion
3.3.1 Determination of CD44 overexpression in B16F10 cells in vitro
CD44 overexpression in many metastatic cancers, including melanoma,
has been utilized as a biomarker and an anti-cancer target for drug and gene
delivery. The amount of CD44 in murine melanoma cells B16F10 was first
confirmed by flow cytometry using FITC-conjugated anti-CD44 antibody (Figure
12a). FITC-conjugated antibody isotype was used as a negative control. The
overlay image of the histograms clearly shows the elevated CD44 expression in
B16F10 cells. In preparation for in vivo testing of the HA-targeted polyplexes, we
have also verified CD44 expression in B16F10 cells stably expressing luciferase
(B16F10.Luc) that allow easy non-invasive optical imaging of the tumor growth
and metastatic spread. To confirm binding of HA to CD44 receptors in B16F10
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cells, FITC-conjugated HA (6K and 60K) was incubated with the cells and uptake
was determined by flow cytometry (Figure 12b and c). The results show that both
low- and medium-molecular-weight HA was able to bind with CD44 receptors
overexpressed in B16F10 melanoma cells. The differences in FITC-HA uptake
between 4 and 37 °C support involvement of energy-dependent endocytosis in
the internalization of HA in B16F10 and B16F10.Luc (Figure 12d). Specificity of
the HA binding and internalization was investigated in polyplexes in studies
described below.

Figure 12. (A) Overexpression of CD44 in B16F10 and B16F10.Luc cells
determined by FACS using FITC labeled anti-CD44 antibody. (B) Cell uptake of
FITC-conjugated low-molecular-weight (6 kDa) HA and (C) medium-molecularweight (60 kDa) HA. (D) FITC-HA (60 kDa) uptake at 4 and 37°C).
3.3.2 Physicochemical characterization of CD44-targeted RHB polyplexes
Several different strategies have been used to modify HA in the past. They
include modification of the carboxyl groups, hydroxyl groups, and the reducing
end of HA (Pouyani and Prestwich 1993; Bulpitt and Aeschlimann 1999; Choi,
Min et al. 2009). When we first attempted direct carbodiimide-mediated coupling
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of primary amines of RHB to HA, negligible coupling efficiency was observed,
most likely due to the protonation of the required nucleophilic nitrogens at the
reaction pH (Luo and Prestwich 2001). Modified carbodiimide chemistry has
been used extensively to modify HA for coupling to other polymeric carriers and
various small molecule drugs. Luo et al. have described a convenient route to
achieve high degree of HA substitution using NHS ester of HA. The NHS-HA has
proven to be a versatile precursor for bioconjugation of HA with a variety of
molecules, including drugs and labeling dyes. In this study, we have thus used
HA-NHS for direct coupling to RHB as well as post-grafting to RHB/DNA
polyplexes.
In this comparative study, three approaches to HA incorporation into
polyplexes were used using two different molecular weights of HA. The main goal
was to determine which of the three approaches provides the best combination of
CD44 targeting, steric stability, and transfection activity of polyplexes.
Size and zeta-potential of the HA-containing RHB/DNA polyplexes were
measured using DLS and the results are summarized in Table 3. Unmodified
RHB/DNA polyplexes show the smallest size of 87 nm with the highest zetapotential. All the polyplexes containing HA with molecular weight 60 kDa,
regardless of the method of preparation, had a relatively small size ranging from
125 to ~280 nm. In contrast, the use of low-molecular-weight HA (6 kDa),
resulted in polyplexes with significantly larger sizes ranging from ~600 to ~800
nm. RHB-6HA and RHB-60HA polyplexes formed by direct complexation of DNA
and HA-RHB copolymers showed the highest positive high zeta-potential,
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probably due to the limited amount of HA in the polyplexes and incorporation of a
portion of HA in the internal structure of the polyplexes. Post-modified
polyplexes, either by the non-covalent or covalent approach, all exhibited
decreased zeta-potential, which was especially pronounced for the 60K HA
covalently post-modified polyplexes. These findings confirm the important role of
molecular weight of HA on achieving steric stability of nanoparticles. The higher
molecular weight HA provided a better stabilization, both by steric and
electrostatic mechanism, than the low molecular weight HA as documented by
both the smaller size of the polyplexes and their lower zeta potential. The results
also suggest that approaches that incorporate HA selectively on the surface of
polyplexes may provide better stabilization and presentation of HA for
subsequent receptor binding. Despite the disappointing results with HA 6 kDa,
there is a possibility to achieve steric stabilization of polyplexes and better
surface presentation of HA by additional incorporation of stabilizing molecules
like PEG.
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Table 3. Hydrodynamic size and zeta-potential of optimized CD44-targeted
polyplexes prepared at w/w 4 (RHB to pDNA).

3.3.3 Stability of HA-containing RHB/DNA polyplexes against serum- and
heparin-induced disassembly
Steric stabilization with PEG has been proven to avoid rapid clearance
and limit non-specific tissue distribution of systemically administered polyplexes
due to less binding with various plasma proteins (Davis 2009). It has been
reported that HA can provide liposomes and polymersomes with similar steric
stabilization as PEG and thus improve systemic circulation (Peer and Margalit
2004; Peer and Margalit 2004; Ito, Yoshihara et al. 2010). In order to assess the
effect of HA on the stability of RHB/DNA polyplexes, all three types of HAcontaining polyplexes were treated with 10% or 50% FBS and 80 µg/ml of
heparin. As shown in Figure 13, RHB was able to condense DNA and protect it
from serum degradation as expected but could not resist disassembly caused by
heparin competition. The increased fluorescence in the starting wells of the
serum-treated samples and the slight smear suggest loosening of the polyplex
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structure and partial release and degradation of DNA from the RHB/DNA
polyplexes. All the HA-containing polyplexes exhibited enhanced stability against
serum as suggested by the decreased fluorescence in the gel compared with
nonmodified polyplexes. Furthermore, polyplexes that were stabilized by covalent
post-grafting

also

showed

enhanced

stability

against

heparin-induced

disassembly. From our previous studies we know that combination of stability
against serum and heparin is a good predictor of prolonged plasma circulation of
polyplexes.

Figure 13. Agarose gel electrophoreses for the optimized polyplexes against
serum and heparin. Four conditions from left to right are: 1) no treatment 2)
+10% FBS 3) +50% FBS 4) +0.5mg/ml heparin, respectively.
3.3.4 Cell uptake and transfection activity of HA-containing RHB/DNA polyplexes
Unmodified RHB/DNA polyplexes have shown high in vitro transfection
efficiency in B16F10 cells by taking advantage of the efficient non-specific cell
uptake and rapid intracellular DNA release due to elevated GSH levels (Chen,
Wu et al. 2009). Here, we have evaluated the targeting and transfection effect of
HA in the three types of HA-containing RHB/DNA polyplexes (Figure 14).
Enhanced cellular uptake in serum-free (-FBS) conditions compared with
unmodified RHB/DNA was observed in the case of HA-RHB polyplexes. No
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increase in the cell uptake was observed for any other HA-containing polyplexes
tested. This confirms that non-specific, charge-mediated cellular uptake of nonmodified polyplexes is highly efficient and that specific receptor-mediated uptake
of polyplexes is a less efficient process despite its selectivity. The observation
that HA-containing polyplexes with the highest positive charge had the highest
cell uptake confirms this conclusion and suggests that the observed uptake is a
combination of non-specific and CD44 specific uptake. In contrast, when cell
uptake was tested in the presence of serum, the HA-containing polyplexes have
maintained or increased their uptake when compared with the unmodified
RHB/DNA polyplexes. This confirms the importance of the HA for stabilizing the
polyplexes and the role serum protein binding plays in the activity of polyplexes.
Surprisingly, HA 6 kDa showed an overall better performance than HA 60 kDa
suggesting a complex relationship between surface shielding, steric stabilization,
and receptor binding of polyplexes.

Figure 14. Cell uptake of the optimized polyplexes. pDNA was labeled with
YOYO-1 before polyplexes preparation and B16F10 cells were incubated with
the polyplexes for 4 h.
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Figure 15 shows the effect of HA on transfection efficiency of the
polyplexes. Mirroring the uptake results, it is obvious that transfection of the HAcontaining polyplexes is less adversely affected by the presence of serum. Again
confirming the importance and benefits of HA stabilization on the properties of
polyplexes. HA-containing polyplexes are thus better suited for in vivo
applications than the non-modified RHB/DNA polyplexes. Regardless of their
type, polyplexes containing HA 6kDa showed better transfection activity than the
corresponding polyplexes containing HA 60 kDa. While some of the effect is
undoubtedly due to higher zeta potential of the polyplexes with HA 6 kDa, there
is a possibility that the some of the effect is also due to the molecular weight
dependence of HA binding to CD44 (Hornof, de la Fuente et al. 2008).
Significantly increased avidity of binding has been observed for HA with
molecular weight above 4.2 kDa due to its divalent binding to CD44 receptors for
which the minimum HA chain length is 20 saccharide residues. No further
increase in binding avidity was observed for HA above 6.4 kDa (Lesley, Hascall
et al. 2000).
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Figure 15. Luciferase transfection efficiency of the optimized CD44-targeted
polyplexes in B16F10 cells.
To determine to what extent is the observed cell uptake and transfection
of HA-containing polyplexes dependent on CD44-specific internalization,
competitive binding experiments were conducted. Cell uptake and transfection
were tested in B16F10 cells pre-treated with anti-mouse CD44 monoclonal
antibody to block the CD44 cell surface receptors and to compete for binding with
the HA-containing polyplexes. In these experiments, only formulations containing
HA 6 kDa were used and the experiments were conducted in serum-containing
conditions. Figure 16 shows significant decrease in both cell uptake and
transfection efficiency of HA-containing polyplexes when cells were pretreated
with anti-CD44 antibody. At the same time, the unmodified polyplexes were not
affected by the antibody pretreatment. These results suggest that CD44-specific
cell uptake plays an important role in the observed activity of HA-containing
polyplexes and that HA can indeed provide receptor specific activity when
incorporated in bioreducible polyplexes.
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Figure 16. Effect of competitive binding on cell uptake and transfection. Cells
were treated with 1 µg/ml anti-murine CD44 monoclonal antibody in DMEM
containing 10% FBS for 30 min before adding polyplexes for another 4 h of
incubation.
3.4 Conclusions
Three different approaches to incorporate HA into the structure of
bioreducible DNA polyplexes have been explored with the goal of improving
steric stability and achieving CD44-selective uptake and transfection. Our results
show that higher molecular weight HA is required for steric stabilization of the
polyplexes, while lower molecular weight HA was beneficial for transfection
activity and CD44-specific cell uptake. Overall, none of the developed
formulations was deemed suitable for advancement into in vivo testing. Further
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studies and development are needed to combine steric stabilization with efficient
CD44-selective transfection into a single formulation.
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CHAPTER 4
CYCLAM-BASED BIOREDUCIBLE POLYMERIC COPPER CHELATORS FOR
GENE DELIVERY AND POTENTIAL PET IMAGING

Please note that the content of this chapter was submitted for publication
in Biomacromolecules. As the first author, I performed all the work described in
this chapter except the determination of degree of branching of the polymers by
LC-MS/MS (contributed by Yu Zhu, the second author) and NMR experiments
and analysis (contributed by Dr. S. Hazeldine, the third author). All the authors
agreed with including their work in this dissertation.

4.1 Introduction
The main advantages of using synthetic gene delivery vectors over viral
delivery systems include enhanced safety profile, more feasible large-scale
production, better control of the nucleic acids release, and providing a large
platform for vector design and engineering. Of great interest in developing
multifunctional carriers for gene therapy is to incorporate bio-imaging probes
such as radiolabels, contrast agents, and fluorophores in the vesicles, for
simultaneous visualization, characterization and quantification of many biological
processes in living subjects (Zrazhevskiy, Sena et al. 2010). Such in vivo imaging
probes could be applied in many imaging tools, including Positron Emission
Tomography

(PET),

Magnetic

Resonance

Imaging

(MRI),

Computed
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Tomography (CT) and Single Photon Emission Computed Tomography
(SPECT).
Cyclam (1,4,8,11-tetraazacyclotetradecane) is one of the best known
chemical structures used in chelating diagnostic imaging probes. It is a
macrocyclic ligand with four secondary amimes that forms highly stable
complexes with virtually all transition metal ions. Macrocyclic chelators and their
metal complexes have numerous biomedical applications, including PET and
MRI (Murugesa, Shetty et al. 2001; Sun, Wuest et al. 2002; Boswell, Regino et
al. 2009). The in vivo stability of the macrocyclic metal chelates is significantly
higher than stability of acyclic chelators such as ethylenediaminetetraacetic acid
(EDTA) (Sun, Wuest et al. 2002). Derivatives of cyclam and its relative cyclen
(1,4,7,10-tetraazacyclododecane) have been subject of intensive research in the
development of PET imaging probes using
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Cu (Leung 2004; Sun, Kim et al.

2004; Boswell, Regino et al. 2009; Jin, Furukawa et al. 2011). Benefits of
cyclams in PET imaging include high complexation affinity and high stability (the
stability constant of complex of cyclam with Cu2+, log K, is 27.2), which
substantially benefit the systemic delivery of these imaging probes (Sun, Wuest
et al. 2002). At the same time,
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Cu shows great promise in PET imaging and

targeted radiotherapy due to its half-life (t1/2 = 12.7 h), decay characteristics (β+
(19%); β- (40%)), and easy large-scale production (Philpott, Schwarz et al. 1995;
Sun, Wuest et al. 2002). The
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Cu-complexes of the bicyclam compound

AMD3100 have been shown to be an effective and stable PET imaging agent to
image CXCR4 positive tumors in vivo (Jacobson, Weiss et al. 2009;
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Nimmagadda, Pullambhatla et al. 2010). The ability to form metal complexes
combined with the cationic nature at physiological pH make cyclam a suitable
building block for designing nucleic acid delivery vectors with the possibility of
easy labeling for simultaneous in vivo PET imaging. There are no previous
reports of cyclam-based polycations used in gene delivery, although several
reports describe incorporation of cyclen into gene delivery systems but their
metal chelates were not described (Xiang, Feng et al. 2010; Huang, Ou et al.
2011; Huang, Zhong et al. 2011; Liu, Ma et al. 2011; Huang, Ren et al. 2012).
This chapter describes the studies on using cyclam as the building block
of reducible polycationic chelators (RPC) that could be used as a novel type of
theranostic vector for combined gene delivery and PET imaging. In this initial
study, the synthesis and effect of Cu(II) complexation with RPC on
physicochemical properties of RPC/DNA polyplexes and their gene delivery
performance in vitro were explored.

4.2 Materials and Methods
4.2.1 Materials
Cyclam was purchased from Alfa Aesar (Ward Hill, MA). Heparin (sodium
salt) was purchased from Sigma-Aldrich (St. Louis, MO). Dulbecco’s Modified
Eagle Medium (DMEM), Dulbecco’s Phosphate Buffered Saline (PBS), Fetal
Bovine Serum (FBS), L-Glutamine, and Penicillin-Streptomycin (Pen-Strep)
solution were from Thermo Scientific (Waltham, MA). All other reagents and
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chemicals were obtained from Fisher Scientific or VWR International unless
otherwise noted.

4.2.2 Synthesis and characterization of RPC
RPC were synthesized by direct Michael addition polymerization of
different molar ratios of cyclam and CBA. Calculated amounts of cyclam and
CBA were weighted and dissolved in methanol/water mixture (v/v 7:3).
Polymerization was allowed to proceed in the dark at 37 °C for 24-48 h and the
reaction was stopped before gelation occurred and access of cylam was added
to complete the reaction. The reaction mixture was then added dropwise to
excess of 1.25 M HCl in ethanol so that pH of the mixture was kept around 3.
The resulting precipitated RPC.HCl was isolated by centrifugation, washed twice
with ethanol to remove excess HCl, and the product was dried in vacuum. The
polymers were then dissolved in water and further purified by dialysis against
water for 2 days (MWCO 1,000 for RPC/3 and MWCO 3,500 for RPC/2 and 1.8).
The polymers were then lyophilized after dialysis.
The polymers were analyzed by 1H NMR to confirm the completion of the
reaction and polymer composition. Weight- and number-average molecular
weights as well as polydispersity index (PDI) were determined by Size Exclusion
Chromatography (SEC) using Viscotek GPCmax chromatography system
consisting of an autosampler, a pump, a CTO-10ASVP Shimadzu column oven,
a refractive index detector, a low- and right-angle light scattering detector, and
OmniSEC

software

for

chromatographic

data

analysis/storage

(Malvern
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Instruments, UK). The columns used in series were single pore AquaGelTM
columns (cat# PAA-202 and PAA-203) by PolyAnalytik (London, ON, Canada).
Sodium acetate buffer (0.3 M, pH 5) was used as an eluent at flow rate of 0.3
mL/min.

4.2.3 Determination of degree of branching
The degree of branching was determined using a degradative method with
LC-MS/MS detection following a published procedure (Christensen, Chang et al.
2006). Two mg of each RPC were dissolved in 1 mL sodium phosphate buffer
(20 mM, pH 7.2) before adding 3.75 mg tris(2-carboxyethyl) phosphine (TCEP)
as a reducing agent to cleave all the disulfide bonds. The mixture was then
stirred at room temperature for 1 h, followed by addition of 2.5 mg of Nethylmaleimide (NEM) to cap the free thiols. The reaction was then kept at room
temperature for additional 2 h. The resulting NEM-derivatized fragments were
analyzed by AQUITY UPLC® TQD system (Waters, MA). Chromatographic
analysis was performed using ACQUITY UPLC® BEH ShieldRP18 column (2.1 x
100 mm, 1.7 µm). A gradient solvent system consisted of 0.1% formic acid (FA)
in acetonitrile (solvent B) and 0.1% FA in water (solvent A). The gradient was
increased from 5% to 95% solvent B over 3 min at a flow rate of 0.2 mL/min.
Spectra were acquired using single ion recording (SIR) mode for m/z=457.46,
713.60, 969.79, 1225.79. The ratio of degraded fragments of terminal (T), linear
(L), single-branched (S) and double-branched (D) cyclam units was determined
by peak integrations in LC-MS/MS chromatograms. The relative degree of
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branching (DB) was calculated using the following equation for AB3 type
polymers (Holter, Burgath et al. 1997):

4.2.3 Formation of RPC complexes with Cu(II)
Cu(II) complexes of RPC were formed by incubating polymer solutions
with CuCl2 in sodium acetate buffer (0.1 M, pH 6.0) for 1 h at room temperature.
Complex formation was evaluated from the changes in absorption spectra (400 800 nm) measured by Synergy 2 Microplate Reader (BioTek, VT).

4.2.4 EtBr exclusion assay
The ability of RPC polycations to condense gWiz-Luc DNA was
determined by EtBr exclusion assay by measuring the changes in EtBr/DNA
fluorescence. DNA solution at a concentration of 20 µg/mL in 10 mM HEPES
buffer (pH 7.4) was mixed with EtBr (1 µg/mL) and fluorescence was measured
and set to 100% using an excitation wavelength of 540 nm and an emission
wavelength of 590 nm. Fluorescence readings were then taken following a
stepwise addition of a polycation solution, and the condensation curve for each
polycation was constructed.

4.2.5 Preparation and characterization of RPC polyplexes
gWiz-Luc DNA solution in 10 mM HEPES (pH 7.4) was prepared to give a
DNA concentration of 20 µg/mL in the polyplexes. Polyplexes were formed by
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adding predetermined volume of polymer to achieve the desired polycation/DNA
weight/weight (w/w) ratio and mixed by vigorous vortexing for 10 s. Polyplexes
were further allowed to stand for 30 min prior to use. The determination of
hydrodynamic diameters and zeta potentials of polyplexes was performed by
Dynamic Light Scattering (DLS). Results were expressed as mean ± standard
deviation (S.D.) of 3-10 experimental runs.

4.2.6 Agarose gel electrophoresis
The disassembly of the polyplexes was examined by agarose gel
electrophoresis using previously published protocol (Manickam, Li et al. 2010).
Briefly, gWiz-Luc DNA polyplexes were incubated under indicated conditions of
different concentrations of heparin with or without a reducing agent (either GSH
or DTT) at 37 °C for 1 h. Samples were then loaded onto a 0.8% agarose gel
containing 0.5 µg/mL EtBr and run for 75 min at 120 V in 0.5x Tris/Borate/EDTA
(TBE) running buffer. The gel was then visualized under UV.

4.2.7 Cell culture
Human breast cancer cell line MDA-MB-231 was a kind gift from Dr. Jing
Li, Karmanos Cancer Institute (Detroit, MI). The cells were maintained in RPMI
1640 medium supplemented with 10% FBS. Murine melanoma cell line B16F10
and human hepatocellular carcinoma cell line Hep G2 were purchased from
ATCC (Manassas, VA). B16F10 cells were maintained in DMEM media
supplemented with 10% FBS and Hep G2 cells were maintained in MEM media
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supplemented with 10% FBS. All the cells were cultured at 37 °C in 5% CO2
atmosphere.

4.2.8 Transfection of DNA polyplexes
All transfection experiments were conducted in 48-well plates with cells at
logarithmic growth phase following a previously published protocol (Read, Singh
et al. 2005). Cells were seeded at a density of 40,000 cells/well 24 h prior to
transfection. On the day of transfection, cells were incubated with the polyplexes
(DNA conc. 2.35 µg/mL) in 170 µL of serum-free or 10% FBS-containing media.
After 4 h incubation, polyplexes were completely removed and the cells were
cultured in complete culture medium for 24 h prior to measuring luciferase
expression. The medium was discarded and the cells were lysed in 100 µL of
0.5x cell culture lysis reagent buffer (Promega, Madison, WI) for 30 min. To
measure the luciferase content, 100 µL of 0.5 mM luciferin solution was
automatically injected into each well of 20 µL of cell lysate and the luminescence
was integrated over 10 s using Synergy 2 Microplate Reader (BioTek, VT). Total
cellular protein in the cell lysate was determined by the Bicinchoninic acid protein
assay using calibration curve constructed with standard bovine serum albumin
solutions (Pierce, Rockford, IL). Transfection activity was expressed as relative
light units (RLU)/mg cellular protein ± SD of quadruplicate samples.

4.2.9 Cytotoxicity of polycations
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Toxicity of polycations was evaluated by MTS assay in MDA-MB-231 and
Hep G2 cells. The cells were plated into 96-well microplates at a density 20,000
cells/well. After 24 h, culture medium was replaced by 150 µL of serial dilutions of
a polymer in serum-supplemented medium and the cells were incubated for 24 h.
Polymer solutions were aspirated and replaced by a mixture of 100 µL serumfree media and 20 µL of MTS reagent (CellTiter 96® AQueous Non-Radioactive
Cell Proliferation Assay, Promega). After 2 h incubation, the absorbance was
measured spectrophotometrically in Synergy 2 Microplate Reader (BioTek, VT)
at a wavelength of 490 nm. The relative cell viability (%) was calculated as
[A]sample/[A]untreated × 100%. The IC50 were calculated as polymer
concentration, which inhibits growth of 50% of cells relative to untreated cells.
The IC50 values were calculated based on “log(inhibitor) vs. response - absolute
IC50” curve fitting procedure in GraphPad Prism, with constrains of Fifty=50,
Top=100 and a formula Y=Bottom+(Top-Bottom)/ (1+10^((LogIC50-X)*HillSlope
+ log((Top-Bottom)/(Fifty-Bottom)-1))).

4.2.10 Statistical analysis
Significant differences between two groups were determined using
Student’s t-test and differences among multiple groups were determined using
ANalysis Of VAriance (ANOVA). A p-value < 0.05 was considered statistically
significant in all cases.

4.3 Results and Discussion
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4.3.1 Synthesis and characterization of RPC
A series of three RPC was synthesized by direct copolymerization of
cyclam and CBA. The polymerization was achieved by Michael addition of
different molar ratios of a disulfide containing bisacrylamide and cyclam (Scheme
5).

Since

cyclam

contains

four

secondary

amines

available

for

the

polymerization, it was important to identify reaction conditions to avoid excessive
crosslinking and formation of a gel. The polymerization conditions were first
optimized by testing different temperatures, solvents and feeding ratios of the two
monomers. The polymerization was found to be easily controlled without rapid
gel formation when conducted in methanol:water (v/v 7:3) at 37 °C. Changing the
cyclam:CBA stoichiometry allowed controlling degree of branching of the
synthesized polymers. Cyclam:CBA molar ratio > 0.9 was needed to avoid gel
formation within 24 h. In this study, three RPC polymers were obtained using
molar feeding ratio of cyclam:CBA molar ratios of 1.5, 1, and 0.9; corresponding
to amine:acrylamide functional group ratios of 3, 2, and 1.8, respectively. The
reaction conditions for each RPC polymer are summarized in Table 4.

Scheme 5. Synthesis of RPC. *Exact location of the CBA attachment could not
be determined. Any of the secondary amines are susceptible to modification.
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The RPC polymers were analyzed by 1H NMR to confirm completion of the
reaction by disappearance of the characteristic CBA acrylamide peaks (5.5 – 6.5
ppm). 1H NMR was also used to determine the composition of RPC. Based on
the integration of the signature peaks (4H) from cyclam (1.8 – 2.0 ppm) and the
signature peaks (4H) from CBA (3.4 – 3.6 ppm) (Figure 17a), the final molar
content of cyclam in each RPC polymer product was determined and the results
are summarized in Table 4. The molecular weights and PDI determined by SEC
are also listed in Table 4. RPC/3 had the lowest Mw of 4,400 while the RPC/2
and 1.8 showed similar Mw of 13,700 and 13,800, respectively. The SEC data
also showed a decrease in PDI with decreasing cyclam content. However, the
low PDI values for RPC/2 and 1.8 might be underestimated considering the
nature of the reaction. This might be due to the limitation of the SEC column to
fully separate branched polycations at low-molecular-weight regions.
Since there are four secondary amines on the cyclam ring available for
reaction, and quick gel formation at feeding ratio (amine to acrylamide) below 1.8
was observed, it was expected that branching occurs and varies depending on
the feeding ratio of the two monomers. To test the degree of branching for each
RPC polymer, each disulfide bond was broken down by a thiol-free reducing
agent TCEP, followed by capping the thiol group using NEM to form a stable
thioether bond. The degradation fragments were then analyzed by LC-MS/MS.
The chemical structure of all the possible fragments and their mass after
ionization (m/z) are listed in Figure 17b. All the four possible degradation
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products could be found in all three RPC polymers. Figure 17c shows an
example of the LC-MS/MS spectrum for RPC/2. Calculated degrees of branching
of RPC polycations are listed in Table 4. The results show that RPC/3 exhibited
the most linear structure when compared with the other two polycations. No
significant difference in the degree of branching was found between RPC/2 and
RPC/1.8.

Figure 17. Characterization of RPC polycations. (A) Typical 1H NMR (D2O)
spectrum (RPC/2); (B) Chemical structures and (C) typical LC-MS/MS spectrum
of reduced RPC/2 fragments.
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Table 4. Synthesis and characterization of RPC polycations.

4.3.2 Copper(II) complexation of RPC polymers
To explore the potential for PET imaging of RPC polymers, nonradioactive
CuCl2 was used in this preliminary study to evaluate if the cyclam moiety in the
RPC polymers retained its ability to form complexes with Cu(II) (Scheme 6).
Cu(II) complexes with RPC were easily prepared in acetate buffer and
characterized by UV-vis spectroscopy (Figure 18). Cyclam was used as a
positive control and CuCl2 was used as a negative control for monitoring free
uncomplexed Cu(II). The results show that for cyclam (Figure 18b), titration with
CuCl2 led to appearance of a peak in the UV-visible spectrum (λmax = 510 nm)
that reached a maximum absorbance when 1 molar equivalent of CuCl2 was
added. The sharp peak at the equivalent point indicates the formation of a welldefined uniform metal complex (Lo, Salam et al. 2011). Addition of excess Cu(II)
gives absorbance above 600 nm, which corresponds to the unbound CuCl2. All
three RPC polymers (Figure 18c-e) showed absorption maximum at λmax = 570
nm that reached maximum absorbance at a near equimolar cyclam:Cu ratio
indicating that cyclam units in the RPC are sterically accessible to Cu(II)
complexation. However, Cu(II) complexes of RPC exhibited broader peaks with
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λmax shifted to higher wavelength, suggesting different Cu(II) complexation ability
caused by the heterogeneity in cyclam structures in the polymers. RPC/1.8
exhibited the broadest absorption peak among the three polymers, a likely
consequence of its highest degree of branching. Overall, all RPC polymers have
retained their ability to form Cu(II) complexes, which makes them promising
theranostic agents for future use in gene delivery combined with PET imaging.

Scheme 6. Structure of the complex of RPC with copper(II).

Figure 18. Cu(II) complexation of RPC polymers (C-E). Cyclam (B) was used as
positive control and CuCl2 (A) was used to monitor free Cu(II). The absorption
spectra were obtained by UV-vis spectroscopy after 1 h incubation with CuCl2.
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The transfection activity of the RPC polycations and their Cu(II) complexes
was tested next. Conformational changes caused by binding with transition metal
ions like Cu(II) (Paisey and Sadler 2004) increase rigidity of the cyclam ring due
to locked positions of the secondary amines. The hypothesis was that the likely
increased rigidity will affect DNA binding ability and polyplex formation of RPC.
The presence of Cu(II) in the RPC structure also increases the overall positive
charge and charge density of the polycations, which may further affect the
electrostatic interactions during the formation of DNA polyplexes, cytotoxicity of
RPC, stability of the polyplexes against disassembly, and ultimately transfection
activity of the polyplexes. Finally, there is a potential for increased toxicity of the
Cu(II) complexes of RPC due to adverse effects of the heavy metal ion itself.
Hence, a comprehensive evaluation of the physical properties and biological
activity of the RPC polycations as well as their Cu(II) complexes was conducted.
RPC with 50% and 100% of the cyclam moieties complexed with Cu(II) were
selected and compared the results with the copper-free RPC.

4.3.3 DNA condensation
To test the DNA condensation capability of RPC and their Cu(II)
complexes, EtBr exclusion assay was conducted (Figure 19). All the RPC were
able to fully condense DNA at w/w > 2 as indicated by no further fluorescence
decrease beyond this ratio, while the cyclam monomer failed to condense DNA
into polyplexes. All three PRC displayed similar condensation curves of typical
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sigmoidal shape. Condensation curves for the Cu(II) complexed RPC polymers
could not be reliably obtained because of the observed fluorescence quenching
by the copper present. Thus, the effect of Cu(II) complexation on improved
binding of RPC could not be determined by this method.

Figure 19. DNA condensation of RPC polymers and cyclam monomer by EtBr
exclusion assay.
4.3.4 Particle size and zeta-potential of DNA polyplexes
The physical properties of DNA/polycation complexes have crucial effect
on both in vitro and in vivo biological performance. Polyplexes with appropriate
size and surface charge greatly benefit the cellular uptake and gene transfer
ability. Hydrodynamic size and zeta-potential of polyplexes were measured by
DLS before every in vitro test. Representative particle size and zeta-potential
data of three RPC polyplexes prepared at different w/w ratios are summarized in
Table 5. The sizes of RPC/DNA polyplexes fell into a broad range of 80-205 nm.
All polyplexes were positively charged with zeta potential ranging from 13 to 29
mV. No significant increase in the surface charge of the polyplexes was observed
above the equivalent w/w ratio 2. Low zeta-potential that was found in RPC/3
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polyplexes prepared at lower w/w ratio is probably due to the low molecular
weight of the polycation.
After complexation with 50% and 100% Cu(II), no significant difference in
surface charge of the polyplexes was observed. However, Cu(II) complexed
RPC/2 and RPC/1.8 polyplexes showed a decreasing trend in the hydrodynamic
sizes with increasing metal complexation. This trend was not found in the Cu(II)
complexed RPC/3 polyplexes. The effect of copper complexation seems to be
more pronounced in the polycations with higher degree of branching.

Table 5. Size and zeta-potential of RPC/DNA polyplexes at different w/w ratios.

4.3.5 Effect of reduction on stability of polyplexes against polyelectrolyte
exchange
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The effect of RPC disulfide reduction on the resistance of the polyplexes
against polyelectrolyte exchange with a competing polyanion heparin was
evaluated by agarose gel electrophoresis (Figure 20). In the absence of a
reducing agent, the polyplexes show first signs of destabilization at a heparin
concentration of 80 µg/mL. In reducing conditions of 20 mM GSH that mimic the
redox status in the cell nuclei (Soundara Manickam and Oupicky 2006), PRC/3
polyplexes disassembled and DNA was released without involvement of heparin.
Polyplexes formed with PRC of more branched structure did not release DNA as
readily as suggested by the fact that 20 mM GSH alone was not sufficient to
destabilize the polyplexes. However, addition of a low concentration of heparin
(40 µg/mL) caused complete DNA release (disappearance of fluorescent signal
in the well) from RPC/2 polyplexes and a higher concentration of heparin was
required to fully release DNA from RPC/1.8 polyplexes. Replacing GSH with a
stronger reducing agent DTT resulted in complete DNA release from all three
polyplexes without the presence of heparin. This result suggests that the
differences in degree of the polycations branching affect sensitivity to reductiontriggered disassembly of polyplexes, with the least branched polycations
exhibiting the highest sensitivity to reduction. This finding is most likely the result
of hindered accessibility of the disulfide bonds to the reductant in the more
branched polycations compared with the less branched polycations.
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Figure 20. DNA release from polyplexes by agarose gel electrophoresis with
heparin -/+ 20 mM GSH or DTT. All the RPC/DNA polyplexes were prepared at
w/w 5.
The polyplex stability of Cu(II) complexed RPC against heparin was tested
using the same gel electrophoresis method as above. Figure 21 shows the
results for RPC/1.8 polyplexes as an example. Cu(II)-free RPC/1.8 polyplexes
started to show signs of disassembly and traces of DNA release at heparin
concentration 70 µg/ml and complete DNA release above 80 µg/ml. For Cu(II)
complexed RPC/1.8 polyplexes, at heparin concentration of 80 µg/ml, only partial
DNA was released. This result shows that the presence of Cu(II) in the
polycation, which is expected to increase charge density of the polycations,
increases the stability of polyplexes against polyanion exchanges. However, this
might not benefit gene delivery efficiency of these RPC polyplexes due to
increased difficulty of polyplex disassembly and DNA release.
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Figure 21. Stability of Cu(II) complexes of RPC/1.8 against heparin disassembly.
4.3.6 Transfection efficiency
In vitro transfection efficiency of RPC polyplexes at different w/w ratios
was evaluated in murine melanoma cell line B16F10 and human breast cancer
cell line MDA-MB-231 (Figure 22). PEI polyplexes at w/w 1.2 (N/P 10) were used
as a positive control. The results showed that in B16F10 cells, all the RPC
polyplexes exhibited high transfection efficiency comparable with PEI above
certain w/w ratio, while the cyclam monomer failed to mediate any significant
transfection. The effect of w/w ratio on transfection activity was especially
pronounced in PRC/3 polyplexes, which might be attributed to the low molecular
weight of the polymer and high sensitivity to disulfide reduction. Serum usually
has negative effect on in vitro transfection activity due to the interaction of
positively charged polyplexes with serum proteins like albumin (Dong, Li et al.
2010; Li, Wang et al. 2012; Zheng, Zhong et al. 2012). Here, the influence of
serum on transfection of RPC/1.8 polyplexes was not as significant as the
negative effect observed for RPC/3 and RPC/2 polyplexes, especially when
prepared at high w/w ratio. In MDA-MB-231 cells, the transfection activity of the
RPC polymers was not as high as in B16F10 cells. Nevertheless, RPC/2 and
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RPC/1.8 still showed transfection activity comparable with PEI in serum-free
condition. Cytotoxicity of RPC polyplexes was significantly higher in MDA-MB231 cells compared with B16F10, thus the results for transfection efficiency of
RPC/2 polyplexes prepared above w/w 20 and RPC/1.8 polyplexes prepared
above w/w 10 are not included in Figure 22b.

Figure 22. Transfection efficiency of RPC polyplexes prepared using different
w/w ratio in (A) B16F10 cells and (B) MDA-MB-231 cells. All transfection
experiments were conducted in serum-free (empty bars) and 10% FBScontaining medium (solid bars) during polyplex incubation.
The in vitro luciferase transfection efficiency of 50% and 100% Cu(II)
complexed RPC polymers were conducted as above using B16F10 cells in the
presence of 10% serum. As shown in Figure 23, for RPC/3 and RPC/2
polyplexes, the transfection efficiency of both 50% Cu(II) and 100% Cu(II)
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polyplexes showed a slight decrease (2- to 5- fold), which might be attributed to
the increased difficulty in intracellular polyplex disassembly due to increased
charge density of the Cu(II) complexes as discussed above. However, RPC/1.8
with 100% Cu(II) complexation showed a 20-fold increase in the transfection
efficiency compared with Cu(II)-free polyplexes. Since the properties of RPC/2
and RPC/1.8 are similar, the most likely explanation for the observed transfection
increase is the higher toxicity (as judged by decreased protein content in the cell
lysate) of the copper complexes of RPC/1.8 as described below.

Figure 23. Transfection efficiency of Cu(II) complexes of RPC polymers in
B16F10 cells in the presence of serum. The RPC and Cu(II) complexed RPC
polyplexes were prepared at w/w 15.
4.3.7 Cytotoxicity
It has been well recognized that bioreducible polycations exhibit
significantly decreased cytotoxicity compared with non-reducible counterparts
(Chen, Wu et al. 2009). Here, the in vitro cytotoxicity of RPC polymers was
evaluated by MTS assay in human breast cancer MDA-MB-231 cells because we
found in the previous transfection experiments that these cells are more sensitive
to the polycation toxicity. The cytotoxicity of RPC was also tested in human liver
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hepatocellular Hep G2 cells, which is a well-recognized cell line model used for in
vitro predictive toxicity screening (Mersch-Sundermann, Knasmuller et al. 2004;
Bokhari, Carnachan et al. 2007) (Figure 24). IC50 values for each polymer in
these two cell lines are summarized in Figure 24b. The cytotoxicity of RPC
polymers is significantly decreased compared with 25 kDa PEI in MDA-MB-231
cells (IC50 14 µg/ml (Wang, Wang et al. 2007)). The cytotoxicity of RPC was
even lower in Hep G2 cells compared with PEI (IC50 18 µg/ml (Wang, Gao et al.
2006)), suggesting decreased toxicity in the liver, which might benefit future in
vivo applications. In both cell lines, RPC with higher molecular weight and higher
degree of branching showed increased toxicity. Interestingly, in MDA-MB-231
cells, RPC/2 showed 2-fold higher IC50 than RPC/1.8, while little difference was
observed in Hep G2 cells, suggesting the cytotoxicity of these polycations is cell
type dependent.

Figure 24. Cytotoxicity of RPC polycations in (A) MDA-MB-231 cells and Hep G2
cells by MTS assay. Calculated IC50 values of RPC are listed in the table (B).
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The cytotoxicity of the Cu(II) complexed RPC polycations was evaluated
by conducting MTS assay in MDA-MB-231 cells as before (Figure 25). For all the
three polycations, 100% Cu(II) complexed RPC polymers had significantly
increased cytotoxicity compared with copper-free RPC. This is most likely due to
increased damage to the cell membrane due to higher charge density and rigidity
of the copper-complexed RPC. No toxicity was observed with equivalent
concentrations of free copper in the form of CuCl2. Interestingly, 50% Cu(II)
complexed RPC had significantly lower cytotoxicity compared with Cu(II)-free
RPC in the case of all three polycations. The reason for this observation remains
unclear but the fact that toxicity of the Cu(II) complexes is highly dependent on
the degree of metal complexation needs to be taken into account when selecting
appropriate doses of 64Cu(II) for future PET imaging.

Figure 25. (A) Cell viability curves of Cu(II) complexes of RPC polycations in
MDA-MB-231 cells by MTS assay. (B) IC50 values calculated from data in (A).
4.4 Conclusions
A new type of bioreducible cyclam-based polymeric chelators for
combined gene delivery and potential PET imaging was developed. These RPC
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polycations could be easily synthesized by one-step Michael addition reaction
and they showed low cytotoxicity, high transfection efficiency in vitro. The
capability of RPC to form Cu(II) complexes makes it promising for future in vivo
simultaneous PET imaging. The Cu(II) complexation of RPC affects polyplex
disassembly process as well as transfection efficiency and cytotoxicity in vitro
depending on the degree of Cu(II) complexation.
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CHAPTER 5
DUAL-FUNCTION CXCR4 ANTAGONIST POLYPLEXES TO DELIVER GENE
THERAPY AND INHIBIT CANCER CELL INVASION

Please note that part of the content of this chapter was published in
Angewandte Chemie Int. Ed. (Li, Zhu et al. 2012). As the first author, I performed
all the work in the paper except for preparing Scheme 7 and determining the
purity of polymer by LC-MS/MS (contributed by Yu Zhu, the second author).
NMR analysis was done by Dr. S. Hazeldine. All the authors agreed with
including their work in this dissertation.

5.1 Introduction
Synthetic polycations have been investigated widely as delivery vectors of
nucleic acid therapeutic. Polycations form polyplexes with the nucleic acids,
thereby protecting them from degradation and facilitating transport across cellular
membranes. Significant effort has been devoted to synthesizing polycations that
have improved transfection activity and reduced toxicity (Schaffert, Troiber et al.
2011). Traditionally, polycations have been viewed as pharmacologically inert
components of delivery systems. This chapter describes a conceptually new
approach that polycations can have both a delivery function as well as
pharmacologic activity, to enhance the therapeutic outcome of gene and RNA
interference therapies. It is a novel class of polycations that not only deliver
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plasmid DNA but also function as CXCR4 antagonists that inhibit cancer cell
invasion and thus could limit metastasis in various approaches to gene therapy
for cancer (Scheme 7).

Scheme 7. Mechanism of action of dual-function polycations as CXCR4
antagonists and gene delivery vectors.

CXCR4

is

a

highly

conserved

transmembrane

G-protein-coupled

chemokine receptor that exclusively binds its ligand CXCL12. Consistent with the
seed-and-soil hypothesis of metastatic dissemination (Burger and Kipps 2006;
Hanahan and Weinberg 2011), the sites of metastasis are determined not only by
the characteristics of the cancer cells but also by the microenvironment of the
specific organ for tumor cell adhesion and support subsequent tumor proliferation
and progression (Harvey, Mellor et al. 2007). This process is often mediated by
chemokine-receptor interactions and several studies showed that cancer cells
utilize chemokine receptor CXCR4 and its sole ligand stromal CXCL12 to
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metastasize to distant sites (Luker and Luker 2006). Upregulation of CXCL12 is
often found in sites commonly affected by metastases in cancer types known to
overexpress CXCR4 (Muller, Homey et al. 2001; Taichman, Cooper et al. 2002;
Liang, Yoon et al. 2005; Chinni, Sivalogan et al. 2006; Rhodes, Short et al.
2011). For example, breast cancer cells often overexpress CXCR4 and their
metastases are commonly found in sites with high levels of CXCL12, including
lung, lymph nodes, liver, and bone marrow (Paget 1989; Muller, Homey et al.
2001; Taichman, Cooper et al. 2002). CXCR4 expression is often associated with
poor survival and aggressive types of cancer (Akashi, Koizumi et al. 2008;
Wallace, Prueitt et al. 2008).
CXCR4/CXCL12 axis regulates survival, proliferation, migration and
invasion of various cancer cells by activating various intracellular signaling
transduction pathways that affect cell survival and migration, including
phosphatidylinositol-3-kinase (PI3K) and the mitogen-activated protein kinase
pathways (Vlahakis, Villasis-Keever et al. 2002; Curnock, Sotsios et al. 2003;
Kayali, Van Gunst et al. 2003; Luo, Manning et al. 2003; Peng, Peek et al. 2005).
CXCR4 also activates Erk1/2, which phosphorylates transcription factors
including Elk-1 to promote cancer cell proliferation and survival (Chang and Karin
2001). CXCR4/CXCL12 is involved in activating focal adhesion complexes and
promoting adhesion through integrins. This combined with increasing secretion of
matrix metalloproteinases that mediate degradation of extracellular matrix
contributes to invasion of cancer cells (Fernandis, Prasad et al. 2004; Hartmann,
Burger et al. 2005; Luker and Luker 2006).
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Among the most widely investigated CXCR4 inhibitors are cyclam
derivatives, including AMD3100 (Dessolin, Galea et al. 1999; Khan, Greenman et
al. 2007; Rosenkilde, Gerlach et al. 2007; Khan, Nicholson et al. 2009; Bridger,
Skerlj et al. 2010; Lam, Bhattacharya et al. 2010). AMD3100 is a highly specific
CXCR4 antagonist, as it inhibits binding to its chemokine ligand CXCL12 and
downstream signaling (De Clercq 2003). The AMD3100 binding site on CXCR4
and its antimetastasis activity have been well studied and characterized (Hatse,
Princen et al. 2002). Receptor mutagenesis studies identified the essential
interaction sites for AMD3100 as being Asp171, 262 in the highly conserved motif
located in the CXCR4 transmembrane domains IV and VI. One cyclam moiety
interacts directly with the carboxyl Asp171 and the other with Asp262. Not all eight
amino groups of AMD3100 are required for that activity (Bridger, Skerlj et al.
2010), making it a suitable building block of potential CXCR4 antagonizing
polycations.
Here, this study describes the design and development of an AMD3100based biodegradable polycations with CXCR4 antagonistic activity with potential
for combined drug/gene cancer therapies. The dual-function polycations prevent
cancer cell invasion by inhibiting CXCL12-stimulated CXCR4 activation, while at
the same time efficiently and safely deliver plasmid DNA into cancer cells.

5.2 Materials and Methods
5.2.1 Materials

101
AMD3100 octahydrochloride hydrate was purchased from Sigma-Aldrich
(St. Louis, MO). The base form of AMD3100 used in synthesis was obtained from
Ontario Chemicals, Inc. (Guelph, ON, Canada). Cell culture inserts (for 24-well
plates, 8.0 µm pores, Translucent PET Membrane, cat# 353097) and BD
MatrigelTM Basement Membrane Matrix (cat# 356237) were purchased from BD
Biosciences (Franklin Lakes, NJ). Human CXCL-12 (SDF-1α) was from
Shenandoah Biotechnology, Inc. (Warwick, PA). L-Glutamine, and PenicillinStreptomycin (Pen-Strep) solution were from Thermo Scientific (Waltham, MA).
G418 sulfate and Minimum Essential Medium (MEM) were from Mediatech, Inc.
(Manassas, VA). Diff-Quick staining kit was from IMEB Inc. (San Marcos, CA). All
other reagents and chemicals were obtained from Fisher Scientific or VWR
International unless otherwise noted.

5.2.2 Synthesis and characterization of RPA
RPA was synthesized by Michael addition of equal molar ratio of
AMD3100 and CBA. Typically, CBA (104 mg, 0.4 mmol) and AMD3100 (200.8
mg, 0.4 mmol) were added into a glass vial containing methanol/water mixture (4
mL, 7/3 v/v). Polymerization was carried out under nitrogen protection in dark at
37 °C for 72 h. Then, additional 20 mg of AMD3100 was added to the reaction
mixture to consume any residual acrylamide groups, and stirred was continued
for another 6 h. The reaction mixture was then added dropwise to excess of 1.25
M HCl in ethanol so that pH of the mixture was kept around 3. The resulting
precipitated RPA.HCl was isolated by centrifugation, washed twice with ethanol
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and dried in vacuum. The polymer was dissolved in water and dialyzed against
water for 2 days (MWCO 3.5kDa) before final freeze-drying.
The polymer was analyzed by 1H NMR to confirm completion of the
reaction from disappearance of the acrylamide signal of CBA. The composition of
the polymer was determined by elemental analysis from N, S, and Cl content
(Atlantic Microlab, Inc., Norcross, GA). Removal of any potentially unreacted
AMD3100 was confirmed by analyzing its content in RPA using LC-MS/MS
(AQUITY UPLC® TQD system, Waters, MA) equipped with AQUITY UPLC®
BEH Shield RP18 column (2.1mm×100mm, 1.7 µm). A gradient of aqueous
solution of (2 mM ammonium formate + 0.1% formic acid) and acetonitrile was
used. AMD3100 was monitored at the parent/daughter ions of (m/z) 503.61 →
(m/z) 105.00.
Weight- and number-average molecular weights and PDI were determined
by SEC using Viscotek GPCmax chromatography system consisting of an
autosampler, a pump, a CTO-10ASVP Shimadzu column oven, a refractive index
detector, a low- and right-angle light scattering detector, and OmniSEC software
for chromatographic data analysis and storage (Malvern Instruments, UK). The
columns used were single pore AquaGelTM columns (cat# PAA-202 and PAA203) by PolyAnalytik (London, ON, Canada). Sodium acetate buffer (0.3 M, pH 5)
was used as an eluent at flow rate of 0.3 mL/min.

5.2.3 Cell culture
Murine melanoma cell line B16F10 and human hepatocellular carcinoma
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cell line HepG2 were purchased from ATCC (Manassas, VA). B16F10 cells were
maintained in DMEM supplemented with 10% FBS. Hep G2 cells were
maintained

in

MEM

supplemented

with

10%

FBS.

Human

epithelial

osteosarcoma U2OS cells stably expressing human CXCR4 receptor fused to
the N-terminus of enhanced green fluorescent protein were purchased form
Fisher Scientific. The cells were cultured in DMEM supplemented with 2 mM LGlutamine, 10% FBS, 1% Pen-Strep and 0.5 mg/ml G418.

5.2.4 Polycation toxicity
Toxicity of polycations was evaluated by MTS assay in Hep G2 cells and
CXCR4+ U2OS cells. The cells were plated into 96-well microtiter plates at a
density of 20,000 cells/well. After 24 h, culture medium was replaced by 150 µl of
serial dilutions of a polymer in serum-supplemented medium and the cells were
incubated for 24 h. Polymer solutions were aspirated and replaced by a mixture
of 100 µl serum-free media and 20 µl of MTS reagent (CellTiter 96® AQueous
Non-Radioactive Cell Proliferation Assay, Promega). After 2 h incubation, the
absorbance was measured spectrophotometrically in Synergy 2 Microplate
Reader (BioTek, VT) at a wavelength of 490 nm. The relative cell viability (%)
was calculated as [A]sample/[A]untreated × 100%. The IC50 were calculated as
polymer concentration, which inhibits growth of 50% of cells relative to untreated
cells. The IC50 values were calculated based on “log(inhibitor) vs. response absolute IC50” curve fitting procedure in GraphPad Prism, with constrains of
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Fifty=50, Top=100 and a formula Y = Bottom + (Top-Bottom)/(1+10^((Log IC50X)*HillSlope + Log((Top-Bottom)/(Fifty-Bottom)-1))).

5.2.5 EtBr exclusion assay
The ability of the studied polycations to condense gWiz-Luc DNA was
determined by EtBr exclusion assay by measuring the changes in EtBr/DNA
fluorescence. DNA solution at a concentration of 20 µg/mL in 10 mM HEPES
buffer (pH 7.4) was mixed with EtBr (1 µg/mL) and fluorescence was measured
and set to 100% using an excitation wavelength of 540 nm and an emission
wavelength of 590 nm. Fluorescence readings were taken following a stepwise
addition of a polycation solution, and the condensation curve for each polycation
was constructed.

5.2.6 Reduction-triggered release of DNA from polyplexes
Redox-triggered disassembly of the polyplexes was examined by agarose
gel electrophoresis. Briefly, gWiz-Luc DNA polyplexes were incubated with or
without 20 mM GSH either in the presence or absence of 0.15 M NaCl at 37 °C
for 1 h. Samples were then loaded onto a 0.8% agarose gel containing 0.5 µg/mL
EtBr and run for 75 min at 120 V in 0.5x Tris/Borate/EDTA (TBE) running buffer.
The gel was visualized under UV.

5.2.7 Formation and characterization of RPA polyplexes
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gWiz-Luc DNA solution in 10 mM HEPES (pH 7.4) was prepared to give a
DNA concentration in the final polyplexes = 20 µg/mL. Polyplexes were formed
by adding predetermined volume of polymer to achieve the desired
polycation/DNA weight/weight (w/w) ratio and mixed by vigorous vortexing for 10
s. Polyplexes were further allowed to stand for 30 min prior to use. The
determination of hydrodynamic diameters and zeta potentials of polyplexes was
performed by Dynamic Light Scattering following previously published method.
Results were expressed as mean ± standard deviation (S.D.) of 3-10
experimental runs.

5.2.8 CXCR4 redistribution assay
CXCR4+ U2OS cells were plated in 96-well plate 18-24 h before the
experiment at a seeding density of 8,000 cells per well. The cells were first
washed with 100 µL assay buffer (DMEM supplemented with 2 mM L-Glutamine,
1% FBS, 1% Pen-Strep and 10 mM HEPES) twice and then incubated with
different concentrations of the polycations or AMD3100 in assay buffer containing
0.25% DMSO at 37 °C for 30 min. In experiments with RPA/DNA and RHB/DNA
polyplexes, DNA concentration was 0.5 µg/mL. Human SDF-1α (CXCL-12) was
then added to each well to make final concentration 10 nM. DMSO alone was
used as the negative control, and hSDF-1α alone was used as the positive
control. After 1 h incubation at 37 °C, the cells were fixed with 4% formaldehyde
at room temperature for 20 min followed by 4-time washing with PBS. All the
images were taken by EVOS fl microscope at 20X.
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The quantification of the receptor redistribution was conducted by
ImageXpress® Micro high throughput imaging system by Molecular Devices
(Sunnyvale, CA). The system enables high-quality imaging of 96-well plates
based on automatic focusing of fluorescently labeled cell nuclei (by DAPI or
Hoechst dye) followed by image analysis by MetaXpress software (High
Throughput Mode) based on the average green fluorescent granule intensity
(internalized GFP-CXCR4). Untreated cells U2OS cells stimulated with 10 nM
CXCL12 were used as negative control (100% CXCR4 translocation) and 300
nM AMD3100 treated cells were used as positive controls (0% CXCR4
translocation). The method was verified by establishing a dose response curve of
AMD3100 and its calculated EC50 was comparable with cell line data sheet from
Fisher Scientific. The operation of the instrument and analysis of the data were
conducted with the help of Steve Swaney at the Center for Chemical Genomics
of Life Sciences Institute, University of Michgan (Ann Arbor, MI).

5.2.9 Cell invasion assay
The upper sides of the transwell inserts were coated with 40 µl Matrigel
diluted in serum-free medium (v/v 1:3) per insert. The 24-well plates with coated
inserts were then placed in 37 °C incubator for 2 h. CXCR4+ U2OS cells were
trypsinized and resuspended in different concentrations of drugs in serum-free
medium for 30 min before adding to the inserts at a final concentration of 10,000
cells in 300 µl medium per insert. 20 nM CXCL12 in serum-free medium as the
chemo-attractant was then added to corresponding wells in the companion plate.
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After 16 h, the non-invaded cells on the upper surface of the inserts were
removed with a cotton swab. The invaded cells were then fixed and stained by
dipping the inserts into Diff-Quick solution. The images were taken by EVOS xl
microscope. Five 20X imaging areas were randomly selected for each insert and
each sample was conducted in triplicate.
Statistical significance of the observed differences in cell invasion was
analyzed using non-parametric ANOVA with Dunn’s multiple comparison test
using GraphPad InStat (v. 3.10). P<0.05 was considered significant.

5.2.10 DNA transfection by RPA/DNA polyplexes
All transfection experiments were conducted in 48-well plates with cells at
logarithmic growth phase. Cells were seeded at a density of 40,000 cells/well 24
h prior to transfection. On a day of transfection, the cells were incubated with the
polyplexes (DNA conc. 2.35 µg/ml) in 170 µL of serum-free or 10% FBScontaining media. After 4 h incubation, polyplexes were completely removed and
the cells were cultured in complete culture medium for 24 h prior to measuring
luciferase expression. The medium was discarded and the cells were lysed in
100 µL of 0.5x cell culture lysis reagent buffer (Promega, Madison, WI) for 30
min. To measure the luciferase content, 100 µL of 0.5 mM luciferin solution was
automatically injected into each well of 20 µL of cell lysate and the luminescence
was integrated over 10 s using Synergy 2 Microplate Reader (BioTek, VT). Total
cellular protein in the cell lysate was determined by the Bicinchoninic acid protein
assay using calibration curve constructed with standard bovine serum albumin
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solutions (Pierce, Rockford, IL). Transfection activity was expressed as RLU/mg
cellular protein ± SD of quadruplicate samples.

5.2.11 Intracellular distribution of RPA/DNA polyplexes
Luciferase DNA was labeled with Label IT®-TrackerTM CX-Rhodamine Kit
(Mirus, Madison, WI) according to manufacturer’s protocol. 120,000 CXCR4+
U2OS cells were plated in glass-bottom dish (MatTek P35GC-0-14-C) 24 h
before the experiment. The cells were incubated with RPA/DNA polyplexes
prepared at w/w 5 (2.35 µg/mL DNA) for 3 h before adding 10 nM hCXCL12. The
cells were incubated for another 1 h before a PBS wash, fixation and imaging by
Perkin Elmer Spinning Disk confocal microscope.

5.3 Results and Discussion
5.3.1 Synthesis and characterization of RPA
Although several reports have described lipid-based delivery vectors that
incorporated

peptide-targeting

ligands

to

increase

delivery

to

CXCR4-

overexpressing cells (Driessen, Fujii et al. 2008; Egorova, Kiselev et al. 2009), no
attempts have been made to synthesize polymeric CXCR4 antagonists that take
advantage of their antagonistic properties to enhance the outcomes of gene
therapies. Here, such polycations, named RPA, were synthesized by direct
Michael addition polymerization of AMD3100 with a disulfide-containing
bisacrylamide CBA (Figure 26a). Excessive crosslinking or gel formation during
the reaction were avoided by optimizing AMD3100:CBA stoichiometry, reaction
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temperature, and the solvent used. Soluble RPA was synthesized using a molar
ratio of AMD3100 to CBA 1:1 in MeOH/water (v/v 7:3) at 37°C. The reaction was
terminated by addition of excess AMD3100 to assure consumption of all residual
acrylamides and presence of the terminal cyclam residues in the prepared RPA.
RPA was purified by precipitation and extensive dialysis using 3.5-kDa molecular
weight cut-off membranes.
The completion of the reaction was confirmed by 1H NMR (Figure 26b).
From the NMR spectrum, there are no unreacted acrylamide residues.
Furthermore, the peaks for the center methylenes of the (CH2)3 sections of the
cyclam rings (~2 ppm) show a double peak with integral intensity ratios of 2:1,
from which we can infer no selectivity in the reaction of CBA with the three
available amines in each cyclam ring. The weight-average molecular weight, Mw,
of the RPA used in this study was 13.9 kDa, and the polydispersity index, Mw/Mn,
was 1.26 (Figure 26c). The purity of RPA was > 99.8% as confirmed by LCMS/MS.
A control bioreducible polycation that lacks CXCR4 activity, RHB, was
synthesized

by

copolymerization

of

CBA

with

N,N-

dimethylaminodipropylenetriamine as described previously in Chapter 3 by
following a published method (Chen, Wu et al. 2009). The RHB had Mw = 11.3
kDa and Mw/Mn = 1.95.
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Figure 26. Synthesis and characterization of RPA. (a) RPA synthesis by Michael
addition polymerization (*any secondary amine of the ring could be substituted
and there could be multiple substitutions per ring); (b) 1H NMR of RPA in D2O;
(c) Size exclusion chromatogram of RPA.
5.3.2 Cytotoxicity of RPA
Bioreducible polycations typically exhibit low cytotoxicity due to rapid
intracellular degradation mediated by GSH. Cytotoxicity of RPA was measured
by MTS assay in HepG2 liver cells and in U2OS osteosarcoma cells
overexpressing CXCR4 (Figure 27). In both cell lines RPA had remarkably low
toxicity compared with 25-kDa poly(ethyleneimine) (PEI) control. The IC50 of
RPA was almost 50 times higher than that of PEI in Hep G2 cells (599 vs. 12
µg/mL) and 116 times higher in U2OS cells (464 vs. 4 µg/mL). The IC50 of
control polymer RHB was 57 µg/mL in Hep G2 cells.
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It is expected that bioreducible polycations have decreased cytotoxicity in
vitro compared with non-reducible polycations such as PEI. However, it is very
unlikely that the bioreducible nature is the only contributor to the remarkably high
IC50 of RPA. It has been reported that the cytotoxicity of polycations is caused
by loss of cell membrane integrity followed by mitochondria-mediated apoptosis
(Moghimi, Symonds et al. 2005). One possible explanation for the results
observed here is that the AMD3100 component in RPA associated with CXCR4
binding ability might decrease cell membrane damage, therefore decreasing the
overall cytotoxicity in vitro.

Figure 27. Comparison of cytotoxicity of RPA and PEI 25 kDa in HepG2 cells
(RPA: , PEI: ) and CXCR4+ U2OS cells (RPA: , PEI: ) determined by
MTS.

5.3.3 Physicochemical characterization of RPA/DNA polyplexes
DNA condensation ability of RPA was first compared with PEI, RHB, and
AMD3100 by EtBr exclusion assay (Figure 28a). The condensation curves for all
three polycations displayed typical sigmoidal shape, characteristic of DNA
condensation by polycations. At pH 7.4, a w/w ratio above 2 was required for
RPA to fully condense the DNA, which was higher than that required in case of
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RHB (w/w 1) and PEI (w/w 0.5). AMD3100 has six secondary amines and two
tertiary amines and is thus, to a very limited extent, also able to condense DNA
as demonstrated by a decrease in EtBr fluorescence by about 30%.
The redox stability of RPA/DNA polyplexes was tested by agarose gel
electrophoresis after GSH treatment. As shown in Figure 28b, 20 mM GSH
triggered DNA release form RPA/DNA polyplexes due to the depolymerization of
RPA, which decreased its affinity to DNA.

Figure 28. (a) DNA dondensation by EtBr Exclusion assay; (b) Reductiontriggered DNA release from RPA/DNA polyplexes (polyplexes were prepared at
w/w 5).
The sizes and zeta-potentials of RPA/DNA polyplexes prepared at
different w/w ratios were measured by dynamic light scattering and the results
are summarized in Table 6. RPA and plasmid DNA formed polyplexes that were
positively charged and had a relatively small size compared with PEI and RHB
polyplexes. The small sizes of RPA polyplexes were further confirmed by Atomic
Force Microscopy (AFM) conducted by Yi Zou from Prof. Guangzhao Mao’s lab
in Department of Chemical Engineering and Material Sciences, Wayne State
University (data not shown).
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Table 6. Sizes and zeta-potentials for different w/w ratios of RPA, RHB and PEI.
w/w

Size (nm)

Zeta-potential (mV)

5

56 ± 0

25 ± 4

10

70 ± 6

28 ± 4

15

57 ± 1

31± 4

20

62 ± 4

33 ± 4

25

57 ± 0

26 ± 4

RHB

5

157 ± 2

31 ± 5

PEI

1.2 (N/P 10)

84 ± 1

33 ± 4

RPA

5.3.4 CXCR4 antagonism of RPA
When CXCL12 binds to CXCR4 it induces downstream signaling through
multiple pathways, including Ras and PI3 kinase. Treatment with CXCR4
antagonists not only prevents the CXCL12-induced downstream signaling but it
also inhibits endocytosis of the receptor (Forster, Kremmer et al. 1998; Orsini,
Parent et al. 1999; Hatse, Princen et al. 2002; Dar, Goichberg et al. 2005). To
evaluate CXCR4 antagonism by RPA and RPA/DNA, CXCR4 receptor
redistribution assay was conducted (Figure 29). The assay uses U2OS cells
stably expressing human CXCR4 receptor fused to the N-terminus of enhanced
green fluorescent protein (EGFP). The assay monitors cellular translocation of
the GFP-CXCR4 receptors in response to stimulation with human CXCL12. Here,
the internalization of the CXCR4 receptors into endosomes in CXCL12stimulated cells was oberved, as suggested by the punctate distribution of the
GFP fluorescence (Figure 29b) away from the original diffuse pattern in non-
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stimulated cells (Figure 29a). To exclude the possibility that the observed effect
was caused by nonspecific electrostatic binding of RPA to the negatively charged
binding site of the CXCR4 receptor, control polycation RHB without AMD3100
moiety was also tested, but no CXCR4 antagonistic properties was observed
(Figure 29f).
Next, we explored whether polyplexes themselves exhibit CXCR4
antagonism. CXCR4 internalization was inhibited more efficiently by RPA/DNA
prepared at w/w 5 (2.5 µg/mL total RPA) than at w/w 1 (Figure 29g and h). DNA
is not fully condensed in polyplexes at w/w 1 (Figure 28a); thus, the formulation
contains only a minimum amount of free RPA. The findings at w/w 1 thus suggest
that the polyplexes themselves may inhibit CXCR4 to some extent. Similar to
RHB polymer, no CXCR4 antagonism was observed with RHB/DNA polyplexes
(Figure 29i), confirming that the specific CXCR4 antagonism of RPA and
RPA/DNA is due to the AMD3100 moiety in RPA.
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Figure 29. CXCR4 antagonism of RPA and RPA/DNA polyplexes. CXCR4
receptor redistribution assay was conducted in U2OS cells expressing GFPtagged CXCR4 (a). Before stimulation with 10 nM CXCL12, the cells were
treated for 30 min with (b) no drug; (c) 0.24 µg/mL AMD3100.8HCl; (d) 1.5 µg/ml
RPA.HCl; (e) 2.5 µg/ml RPA.HCl; (f) 1.5 µg/ml RHB.HCl; (g) RPA/DNA
polyplexes (w/w 5, total RPA conc. 2.5 µg/ml); (h) RPA/DNA polyplexes (w/w 1,
total RPA conc. 0.5 µg/ml); and (i) RHB/DNA polyplexes (w/w 5, total RHB conc.
2.5 µg/ml). The scale bars for all the images are 200 µm.
To determine the half-inhibitory (EC50) concentrations of RPA, the
CXCR4+ U2OS cells were treated with increasing concentrations of RPA.HCl
before stimulating them with human CXCL12. AMD3100 was used as positive
control. The level of CXCR4 antagonism was evaluated by quantifying the
fluorescent intensity of granules (endocytosed GFP-CXCR4) in the individual
images. The dose-response curves for AMD3100 and RPA.HCl were established
based on % CXCR4 translocation and EC50 values were calculated accordingly
(Figure 30). Based on the results of elemental analysis (data not shown), the
equivalent AMD3100 content in RPA could be obtained (60% weight of
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RPA.HCl). Thus the efficacy of AMD3100 moieties in RPA.HCl decreased about
50 fold compared with the free drug. The compromised CXCR4 antagonism of
polymerized drug is acceptable considering its secondary function as gene
delivery vector. Excess of polycations is usually required in the polyplex
formulations in order to achieve efficient transfection and the required RPA
concentrations fall in the range needed for safe and efficient gene delivery.
However, the efficacy of RPA could be further improved by better polymer design
since it is most likely that only the terminal AMD3100 moieties in the RPA
polymer chains have retained their antagonistic ability.

Figure 30. Dose-dependent CXCR4 antagonistic ability of AMD3100 and
RPA.HCl. (a) Representative images of redistribution of CXCR4 receptors on
U2OS cells treated with increasing concentrations of AMD3100 and RPA; (b)
Dose-response curve of CXCR4 inhibition (% receptor translocation) and
calculated EC50 value based on images obtained from (a).
5.3.5 Antimetastatic ability of RPA by cell invasion assay
The CXCR4/CXCL12 axis plays a critical role in cancer metastasis due to
its function in trafficking and homing of cancer cells to organs that express high
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levels of CXCL12. Blocking the CXCR4/CXCL12 interactions with small-molecule
antagonists suppresses metastasis in a variety of cancers (Yoon, Liang et al.
2007; Liang, Zhan et al. 2012). To further confirm the CXCR4 antagonism of
RPA and RPA/DNA polyplexes, the anti-metastatic ability was evaluated by a
Matrigel cell invasion assay. As shown in Figure 31, RPA and RPA/DNA
polyplexes effectively block CXCL12-mediated invasion of CXCR4+ U2OS cells.
Both free RPA and RPA/DNA blocked invasion of 71-77% of cells, similar to that
of AMD3100 (75%). The DNA dose used in the experiment with the polyplexes (1
µg/mL DNA) was in the range of typical doses used in transfection experiments.
The observed decrease in cell invasion with control RHB/DNA polyplexes was
not statistically significant (p > 0.05). At the same time, the differences between
RPA and RPA/DNA polyplexes vs. untreated controls were highly significant with
P<0.001, based on non-parametric ANOVA analysis with Dunn’s multiple
comparison test. The slight decrease in the number of invaded cells with RHB
treatment could also be attributed by higher toxicity of RHB compared with RPA.
The membrane damage caused by the treatment with RHB may affect the
motility of the cells and thus decrease their ability to invade through the
extracellular matrix.
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Figure 31. Inhibition of cancer cell invasion by RPA and RPA/DNA polyplexes.
(a) Cell invasion assay with CXCR4+ U2OS cells treated with 1) no drug; 2) 0.24
µg/mL AMD3100.8HCl; 3) 2 µg/ml RHB.HCl; 4) 2 µg/ml RPA.HCl; 5) 5 µg/ml
RPA.HCl and 6) RPA/DNA polyplexes (w/w 5, total RPA conc, 5 µg/ml). Cells
were seeded in Matrigel-coated inserts and allowed to invade towards CXCL12containing medium for 16 h before fixation and imaging. (b) Average number of
invaded cells in 20× imaging area.
5.3.6 Transfection of RPA/DNA polyplexes
Having confirmed CXCR4 antagonism and inhibition of cancer cell
invasion of the synthesized RPA, we then evaluated its gene delivery capability
(Figure 32). A routine luciferase transfection experiment was conducted.
RPA/DNA polyplexes exhibited high in vitro transfection efficiency that was
comparable with that of control PEI/DNA polyplexes and RHB/DNA in B16F10
and U2OS cell lines at a DNA dose of 2.35 µg/mL. It is interesting that AMD3100
itself was able to mediate some transfection, especially in B16F10 cells when
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compared with naked DNA only. As shown in Figure 28, the partial DNA
condensation is the most likely reason for the observed transfection, which is
nevertheless several orders of magnitude below transfection of the polymers.

Figure 32. Transfection activity of RPA/DNA polyplexes prepared at w/w 5, 15
and 25 in the absence (white bars) and the presence (black bars) of 10% FBS in
(a) B16F10 and (b) CXCR4+ U2OS cells. (Results are shown as mean luciferase
expression in RLU/mg protein ± SD, n=3).
5.3.7 Simultaneous CXCR4 antagonism and gene delivery
CXCR4 antagonism by RPA does not require the polymer to be
internalized, which is advantageous because no intracellular barriers need to be
overcome (Wu, Liu et al. 2010). However, because the CXCR4 receptor is not
internalized in the presence of an antagonist like RPA, binding of RPA/DNA to
this receptor would be unproductive in mediating transfection. Polyplex
transfection by CXCR4-mediated uptake was clearly unsuitable in experiments
that attempted to use AMD3100 to target PEI polyplexes to CXCR4overexpressing cells. The authors found no significant increase in transfection
unless phorbol myristate acetate (PMA) was used to trigger CXCR4 receptor
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endocytosis (Le Bon, Craynest et al. 2004). Here we show that RPA/DNA
polyplexes use an alternative uptake pathway that does not require CXCR4. This
is documented by the lack of signal from RPA/DNA polyplexes with fluorescently
labeled DNA colocalized with the membrane-present CXCR4 receptor. As shown
in Figure 33, after 3 h incubation with RPA/DNA polyplexes, the CXCR4+ U2OS
cells were stimulated with hCXCL12 and the confocal image (taken in the middle
of the Z-stack) shows more clearly that the GFP-CXCR4 receptors are mostly
presented in the cell membrane. At the same time, labeled RPA/DNA polyplexes
(red fluorescence) are shown internalized into the cells and notbound with the
membrane-localized CXCR4 receptors. We thus hypothesize that the polyplexes
are internalized through a different endocytic pathway that does not involve
CXCR4.

Figure 33. Intracellular distribution of RPA/DNA polyplexes in CXCR4+ U2OS
cells (red fluorescence: CX-Rhodamine labeled plasmid DNA; green
fluorescence: GFP-CXCR4 receptor).
To further study if CXCR4 inhibition affects the gene delivery function of

121
RPA/DNA polyplexes, AMD3100 was used to block the cell surface CXCR4
receptors before conducting transfection. No significant difference was observed
in transfection efficiency in CXCR4+ U2OS cells either with or without CXCL12
simulation (Figure 34). The results suggest that the uptake of RPA/DNA
polyplexes is not dependent on binding with CXCR4 receptors.

Figure 34. Effect of CXCR4 stimulation/inhibition on RPA/DNA transfection.
CXCR4+ U2OS cells were pre-treated with 300 nM AMD3100 for 15 min before
adding polyplexes prepared at different w/w ratios. The cells were then
stimulated with 10 nM CXCL12 and co-incubated with the polyplexes during
transfection.
It has been reported that CXCL12 and phorbol esters trigger CXCR4
internalization through entirely different uptake pathway (Signoret, Oldridge et al.
1997). AMD3100 only inhibits CXCL12-induced CXCR4 endocytosis, but does
not affect phorbol ester-induced receptor internalization (Hatse, Princen et al.
2002). Here, CXCR4+ U2OS cells were treated with RPA/DNA polyplexes or
AMD3100 before incubation with 100 ng/mL of phorbol 12-myristate 13-acetate
(PMA) and the cells were imaged by fluorescence microscope (Figure 35). The
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results show that internalization of CXCR4 receptor is not inhibited by RPA/DNA
polyplexes similarly to AMD3100 when the cells are stimulated with phorbol
myristate (PMA).

Figure 35. AMD3100 and RPA do not inhibit phorbol-stimulated CXCR4
internalization. CXCR4+ U2OS cells were treated with AMD3100.8HCl (0.24
µg/mL) and then stimulated with a) 10 nM CXCL12 or b) 100 ng/ml of phorbol
myristate acetate. c) CXCR4+ U2OS cells were treated with RPA/DNA (w/w 5)
polyplexes (i.e., 0.5 µg/mL RPA, 0.1 µg/mL DNA) and then stimulated with 100
ng/ml of phorbol myristate acetate.
To further confirm if CXCR4 is involved in the transfection process of the
polyplexes, we evaluated the effect of PMA treatment on transfection activity of
RPA/DNA polyplexes. The experiment was conducted using the same conditions
as described above, except that the cells were co-incubated with polyplexes and
100 ng/mL of PMA in serum-free medium for 4 h. No cytotoxicity of PMA was
observed under the used experimental conditions. The hypothesis was that PMAinduced CXCR4 internalization would improve cellular uptake of the polyplexes
and that this would lead to improved transfection efficiency if polyplexes were
internalized by CXCR4-dependent endocytic pathway. The results show that
PMA did not enhance transfection of RPA polyplexes despite its ability to trigger
internalization of the CXCR4 receptor by an alternative pathway from CXCL12
(Figure 36). This finding provides further support for the lack of involvement of
the CXCR4 receptor in transfection activity of RPA/DNA.
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Figure 36. Effect of phorbol myristate (+/- PMA) treatment on transfection activity
of RPA/DNA prepared at w/w 5, 15 and 25.
Importantly for practical utility of the dual-function polycations, we also
show concurrent CXCR4 inhibition and transfection with RPA/DNA polyplexes
(Figure 37). CXCR4+ U2OS cells were plated in black 96-well plate with optical
bottom 24 h before the experiment at a seeding density of 8,000 cells per well.
The cells were incubated with RPA/DNA polyplexes prepared at w/w 5, 10 and
15 (2.35 µg/mL DNA) or RHB/DNA polyplexes (negative control) prepared at w/w
5 in serum-free media. The polyplexes were removed after 4 h incubation and
the cells were continued to grow in fresh complete culture media. The luciferase
transfection was measured after 24 h. The CXCR4 antagonism was evaluated in
the same cells at 0 h and 24 h after polyplex incubation by stimulating the cells
with

10

nM

hCXCL12.

The

results

show

that

RPA/DNA

polyplexes

simultaneously inhibit CXCR4 (Figure 37a) and mediate effective transfection
(Figure 37b). Additionally, RPA/DNA polyplexes maintain their CXCR4 inhibiting
properties even after 24 hours (although the inhibition was not as complete as in
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the early time point as judged by the reappearance of the punctate fluorescence
distribution of the CXCR4 receptor at 24 h in Figure 37a). In contrast, the
negative control (RHB/DNA polyplexes) shows no CXCR4 antagonism at any
time point, while mediating similar transfection activity as RPA/DNA. These
findings support our proposed mechanism of action in which the free RPA inhibits
CXCR4 while the rest of the RPA/DNA polyplex formulation participates in
transfection, most likely through nonspecific charge-mediated uptake.

Figure 37. Simultaneous transfection and CXCR4 inhibition by RPA/DNA
polyplexes in CXCR4+ U2OS cells. a) Cells treated with RPA/DNA polyplexes
(RPA/DNA w/w = 5, 10 and 15) showed CXCR4 inhibition both at 0 h and, a
weaker one, at 24 h after polyplex incubation. In contrast, RHB/DNA polyplexes
(RHB(5)) showed no CXCR4 antagonism at any time. b) Simultaneously,
RPA/DNA polyplexes exhibit similar transfection (luciferase expression) as
control RHB polyplexes at 24 h after polyplex incubation.
5.4 Conclusions
In summary, we have described the preparation of a synthetic polycation
that functions as a CXCR4 antagonist capable of blocking cancer cell invasion
while simultaneously effectively delivering plasmid DNA and mediating
transfection. Such dual-function delivery vectors can enhance antimetastatic
efficacy of a variety of cancer gene therapy protocols.
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ABSTRACT
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Gene therapy is a promising therapeutic strategy to treat diseases caused
by single or multiple gene mutations. Non-viral gene delivery vectors exhibit
many advantages over viral vectors, including enhanced safety, versatility in
choosing different types of therapeutic nucleic acids, and ease of formulation.
However, low transgene efficiency and lack of targeting ability remain major
challenges. Bioreducible polyplexes (polyelectrolyte complexes of disulfidecontaining polycations and nucleic acids) utilize the redox potential gradient
existing between extracellular space and intracellular environment as a
physiological stimulus to enhance delivery of therapeutic nucleic acids to the
subcellular space. Bioreducible containing polyplexes undergo intracellular
reduction mediated GSH, which results in fast disassembly of the polyplexes and
degradation of the delivery vector, leading to increased transfection efficiency
and decreased cytotoxicity.
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In this dissertation, we first evaluated the effect of enhanced reductive
disassembly

on

transfection

activity

of

plasmid

DNA

and

antisense

oligonucleotide (AON) polyplexes using on a series of synthesized bioreducible
poly(amido amine)s (PAA). We found that increasing the disulfide content in PAA
increased susceptibility to reduction-triggered DNA and AON release from the
polyplexes. However, increasing disulfide content in PAA resulted in increased
DNA transfection only and had no effect on AON transfection. We discovered
that plasma membrane protein thiols played a key role in the observed
enhancement of DNA transfection.
We then explored the possibility of introducing targeting moiety (hyaluronic
acid, HA) into the design and formulation of the bioreducible polyplexes to
stability polyplexes and to achieve selective delivery to CD44 expressing
cancers. Three different approaches to incorporate low- and medium-molecularweight HA into the structure of bioreducible DNA polyplexes have been explored
with the goal of improving steric stability and achieving CD44-selective uptake
and transfection. Our results show that higher molecular weight HA is required
for steric stabilization of the polyplexes while lower molecular weight HA was
beneficial for targeted transfection activity. Further studies and development are
needed to combine steric stabilization with efficient, CD44-selective transfection
into a single formulation.
Our next goal was to develop multifunctional bioreducible polyplexes for
combination gene therapy in a single formulation. We have developed a series of
bioreducible

polycationic

copper

chelators

(RPC)

based

on

1,4,8,11-
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tetraazacyclotetradecane (cyclam). We confirmed that the cyclam moieties in the
polycations retained their ability to form complexes with Cu(II). The presence of
disulfide bonds in the polycations resulted in substantially lower cytotoxicity than
control 25 KDa PEI and both the Cu(II)-free and Cu(II) complexed polymers
exhibited high transfection efficiency in vitro. This novel type of polycationic Cu(II)
chelates represent promising nucleic acid delivery vectors with potential for PET
imaging using 64Cu radioisotope. We further designed and developed a cyclambased dual-function bioreducible polycations that function simultaneously as
gene delivery vectors and as CXCR4 antagonists. We found that these dualfunction polycations with their own pharmacological activity are able to prevent
cancer cell invasion by inhibiting CXCL12 stimulated CXCR4 activation, while at
the same time efficiently and safely delivers plasmid DNA into cancer cells.
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